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BCT is generally associated 
with fewer complications,  
similar QoL, and lower  
resource use, leading to  
superior cost-effectiveness 
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Breast cancer is the most common type of cancer in women in the Nether-
lands, with a lifetime risk of 1 out of 8 and about 17,000 new cases annually.1 
Immediately after receiving the diagnosis breast cancer, a patient needs to 
decide together with her surgeon, which type of surgical treatment is optimal. 
The first decision is between mastectomy or breast conserving surgery followed 
by radiation therapy (breast conserving therapy, BCT). If the patient and her 
surgeon opt for mastectomy, the patient is presented with an additional set 
of choices, namely whether she wants her breast to be reconstructed and if 
so, how. These choices lead to a multitude of possible treatment pathways 
to choose from. Currently, the impact of a choice for one of these pathways 
on the treatment burden, health-related quality of life outcomes and healthcare 
resource use is unclear, due to limited and often conflicting evidence presented 
in the literature. This complicates the decision-making process for both patient 
and surgeon. 
The current PhD-project aimed to reduce this uncertainty by making innovative 
use of the state-of-the-art healthcare registrations that are currently in place 
in the Netherlands. These registrations allow extensive information to be 
gathered on the complete breast cancer related healthcare use of a large 
cohort of patients and combine it with comprehensive, national patient and 
cancer treatment databases, such as the National Cancer Registry (NCR). 
These registration systems were additionally used to identify and approach 
breast cancer patients to investigate the long-term health-related quality of 
life after four common surgical treatment options for breast cancer and the 
effect of complications.
Methods of postmastectomy breast reconstruction
If a mastectomy has to be performed, the patient may decide she wants her 
breast to  be reconstructed. In general, there are two main types of breast 
reconstruction (BR): either using implants or autologous tissue. Each of these 
BR types have advantages and disadvantages which are discussed in the 
following paragraphs. The reconstruction of the breast is often followed by 
additional operations to improve symmetry or treat complications, followed 







n Implant-based breast reconstructionWith the introduction of silicone breast implants in 1964, the era of modern BR began. 
In the decades following, the quality of implants has improved, and implant-based BR is 
widely used. BR by using implants is a relatively straightforward procedure with reduced 
operative time, a relatively short postoperative recovery and a lack of donor-site morbidity. 
Implant-based techniques can therefore be performed in basically all hospitals treating 
breast cancer patients.
Implant-BR may be performed either as a one-stage (direct insertion of a definite 
prosthesis) or as a two-stage procedure (insertion of a tissue expander followed by 
replacement with a definite implant during a second procedure). However, a one-stage 
reconstruction may not be feasible in all patients and is generally recommended only 
in specific situations. Frequently, it is necessary to stretch the deficient local skin and 
muscles using a tissue expander (silicone balloon) to create adequate soft tissue 
coverage of the breast implant. Postoperatively, the tissue expander (TE) is gradually 
inflated using injections with saline during weekly visits to the outpatient clinic.
An important disadvantage of implants inserted in the human body is the formation of 
a surrounding capsule of scar tissue, which is a natural response (foreign body reaction) 
and is a frequent reason for implant removal or replacement. This capsule may contract 
over time, which tightens and squeezes the implant (capsular contracture). Besides 
physical complaints such as pain and discomfort, capsular contracture also can cause 
a distortion of the appearance of the breast, thereby negatively affecting the aesthetic 
result. Implant rupture is another frequent reason for implant removal or replacement. 
Approximately 50% of all women who have opted for breast reconstruction using 
implants require reoperation in the long-term.3
In the last couple of years, an increasing number of reports have shown a considerably 
larger risk of the development of a rare and potentially lethal anaplastic large cell 
lymphoma (BIA-ALCL) after implant-BR than was previously assumed.4 This finding has 
been widely picked-up by the media and has led to a ban for certain breast implant 
types in some countries over the world. It has also led to fear and many questions 
among patients that previously have undergone implant-BR as well as patients that have 
to decide on the type of BR.
Autologous breast reconstruction
A breast mound may also be reconstructed using autologous tissue only. Excess skin 
and fat with or without the underlying muscle from basically anywhere in the body 
can theoretically be used. However, usually abdominal tissue is used because of its 
availability and relatively low donor-site morbidity. The Transverse Rectus Abdominis 
Myocutaneous (TRAM) flap includes skin, fat and muscle from the lower abdomen which 
is transferred to the chest wall.5 It can either be used as a pedicled (where the 
bloodvessels remain connected to their origin) or free flap (where the bloodvessels are 
reattached to a bloodvessel in another location) requiring a smaller proportion of the 
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which compared patients with implant-BR and autologous-BR two years after their 
surgery.15 They found that autologous-BR patients were generally more satisfied with 
their breasts and had better psychosocial and sexual well-being as measured with the 
Breast-Q. Furthermore, outcomes measured over a longer period of time would be of 
interest, as different surgical outcomes may have a different HRQoL-course over time. 
For example, recovery from surgical complications takes additional time with at least 
a temporary negative effect on HRQoL.16, 17
Unfortunately, BR has a relatively high risk of postoperative complications that can 
sometimes even result in the complete loss of the reconstructed breast (BR-failure). 
A recent large, prospective study reported BR overall complication rates of 26.6-31.3% 
for implant-BR and 35.8-47.4% for autologous-BR techniques with BR-failure rates of 
7.1% and 1.3-2.1% respectively.18
Few studies have investigated the potential negative psychological consequences of 
a BR-failure. One recent qualitative study showed that an autologous-BR failure has a 
large emotional impact on patients.19 Quantitative studies by our research group have 
shown that postoperative complications (including BR-failures) were associated with 
substantial psychological distress in the short-term, but that in the long-term these levels 
of distress returned to values comparable to that of patients without such postoperative 
complications.16, 20 However, quantitative studies provide only limited insight into which 
experiences lead to distress in patients confronted with a BR-failure. Qualitative studies 
that investigated the effect of an implant-based BR-failure on patients’ quality of life can 
provide more information but are lacking so far. In addition, plastic surgeons who perform 
the procedure may also be affected by the event of a BR-failure. Several studies have 
shown that the occurrence of serious adverse events may have a strong impact on the 
healthcare provider involved, also referred to as the “second victim” phenomenon.21, 22 
Evaluating health economic outcomes: QALYs and CUA
The formal way of evaluating the value of a healthcare intervention is by performing 
a cost-effectiveness analysis (CEA). Strictly speaking, in this kind of analysis any 
effectiveness measure could be used, however, through the years the norm has become 
to use the “quality adjusted life year” (QALY) as the effect measure. The reasoning for 
the use QALY’s is that interventions in healthcare can have an effect on two outcomes: 
survival and quality of life. Both are important to consider in economic evaluations of 
healthcare interventions and both can be used to justify costs. Analyses that use QALYs 
as the effect measure are formally called cost-utility analysis (CUA), however, they are 
still more frequently referred to as CEA.
Currently, QALYs are most often measured using generic preference-based health status 
measures (GPBM). Examples of such measures are the EQ-5D, the SF-6D and the HUI3. 
It has been claimed that these generic health-related quality of life measures can be used 
for all interventions and patient groups.23 This generic property is of great value in CUA 
abdominal muscle. Currently, the most popular autologous method is the Deep Inferior 
Epigastric artery Perforator (DIEP) flap, also using abdominal fat and skin, but leaving 
the abdominal muscles intact, which reduces the chance of abdominal muscle weakness 
or hernia formation.6 
At the Erasmus MC in Rotterdam, this latter technique has been performed since 2001. 
Advantages of this BR procedure are: there is no need for foreign material to reconstruct 
a breast; damage to the abdominal wall is minimized compared to pedicled or free 
TRAM flap techniques; and the reconstructed breast is similar to a natural breast that 
feels warm, is soft with a natural appearance and adjusts to body weight fluctuations.6 
However, compared to implant techniques, the DIEP-flap technique takes profoundly 
longer in terms of operative time and recovery. In addition, a large abdominal donor-site 
wound bed is created after harvesting tissue that is needed for reconstruction which may 
lead to donor-site morbidity.
Evaluating patient-reported outcomes:  
PROMs and HRQoL
In recent years large changes have emerged in how healthcare interventions are 
evaluated. Most notable are the introduction of Patient-Reported Outcome Measures 
(PROMs) and the concept of value-based healthcare which states that providing high 
value for patients should become the overarching goal of healthcare delivery.7 The patient 
has become the center of attention using PROMs to assess the impact of their disease 
and treatment on their quality of life, which is becoming the new benchmark to which 
treatments must measure up. Ideally, value to the patient should guide performance 
improvement in healthcare. Rigorous, disciplined measurement and improvement of this 
value would be the best way to drive system progress.7, 8
Research has shown that Health-Related Quality of Life (HRQoL) is relatively high in 
breast cancer patients following treatment compared to other types of cancer, but 
evidence about possible differences in HRQoL after different treatment options is 
conflicting.9-12 For instance, there are both studies that did and did not find differences 
in HRQoL between patients who had undergone BCT or mastectomy.13 Also, several 
higher quality studies did not find statistically significant differences in HRQoL, body 
image, and sexuality between patients with or without BR.14 This conflicting evidence may 
be explained by variation in the use of PROMs, study designs, and patient populations. 
The impact of different surgical breast cancer treatment possibilities on HRQoL is in need 
of a reexamination, because valid information about the outcome of treatment options is 
vital for informed clinical decision-making and healthcare policy makers.
Until now, outcomes have been generally measured in small, cross-sectional, mono- 
center studies, which can explain the conflicting evidence found. Ideally, one would 
have to include all surgical options relevant to breast cancer patients in one large 
prospective cohort study.14 Santosa et al. performed such a large prospective study, 
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as the direct comparison of the cost-effectiveness of different interventions is one of the 
key reasons for performing such an analysis. The questionnaire used in this thesis is 
the EQ-5D. In the paragraph below this instrument is discussed in more detail.
The EQ-5D is a widely-used generic health-related quality of life (QoL) instrument, 
designed to measure the most important aspects of health over a broad spectrum of 
health conditions and diseases.24 The instrument is specifically used in health economic 
appraisals where comparisons between very different therapeutic areas/ specialties are 
made to substantiate the allocation of resources. The EQ-5D was specifically designed 
to measure the ’Q’ in QALY and is notably different from other questionnaires used to 
measure QoL. It provides ‘preference-weighted’ quality of life scores (utilities), based on 
the values that the general public assigns to different health states, which are needed 
for the calculation of QALYs. An increasing number of reimbursement agencies are 
requiring a GPBM being the standard outcome measure, with NICE in the UK and 
ZiNL in the Netherlands requiring the EQ-5D to be used as the effect measure of 
choice.25-27 This claim of universal applicability holds true for many conditions, however, 
for some conditions these GPBMs have been found not to be sensitive enough or to lack 
relevance.23 It is unclear whether this is also the case for breast cancer surgery, most 
notably breast reconstruction interventions, for which the limited attributes included in 
the instrument may be unsuitable to detect the effects of the intervention on quality of 
life. It is therefore important to first evaluate whether the EQ-5D is a valid instrument 
for the evaluation of QoL in BR patients.
Formally evaluating value of breast cancer  
treatment pathways
Beside the trade-off between risks and benefits for the patient, different treatment 
pathways have different costs consequences. These differences in costs are relevant, as 
healthcare budgets are under substantial strain due to the increasing healthcare costs. 
Society, policy makers and insurance companies are therefore confronted with complex 
choices about which medical interventions to reimburse. Within such deliberation, 
the cost-effectiveness of the interventions, is an eminent argument. This is not only 
relevant when choosing between surgical pathways for breast cancer treatment, but 
also when the reimbursement of these surgical pathways is in competition with other 
allocations of the healthcare budget. This is particularly relevant for common surgical 
treatment pathways for breast cancer such as BR, as these are not life-prolonging. If the 
outcome of not life-prolonging interventions is measured in QALYs, the outcome can 
then be compared with life-saving interventions. Evidence that a given surgical treatment 
has a favorable cost-effectiveness will help to strengthen its position.
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Aims and outline of the thesis
The first part addresses the measurement of health-related quality of life in breast cancer 
patients after breast cancer surgery and breast reconstruction. In Chapter 2 the validity 
of the EQ-5D for BR following mastectomy for breast cancer was evaluated in a large 
cohort of patients with a long follow-up. This allowed us to assess whether EQ-5D 
outcomes were suitable for further use in cost-utility-analyses. In chapter 3 the long-term 
health-related quality of life after four common surgical treatment options for breast 
cancer and the effect of complications was retrospectively investigated in 1871 patients. 
This chapter aimed to compare QoL outcomes of BCT, mastectomy, mastectomy 
followed by autologous-BR, and mastectomy followed by implant-BR. QoL was 
assessed using multiple PROMs in a large, multicenter, retrospective, cross-sectional 
cohort of breast cancer patients up to ten years after diagnosis. Furthermore, the 
impact of complications on QoL following these different surgical treatment options was 
also investigated.
The second part of this thesis consists of state-of-the-art cost-effectiveness analysis 
which aimed to formally compare the value of the four most common breast cancer 
treatment pathways. In chapter 4, the cost-effectiveness of these pathways was 
compared. Because the outcomes of the different surgical pathways may be affected 
by postoperative complications, we also assessed the impact of complications following 
these four different surgical treatment pathways, on the costs.
The third part of this thesis takes a qualitative approach to evaluate the impact of 
complications after BR surgery on both the patient and the surgeon. Chapter 5 addresses 
patients’ and surgeons’ experiences after failed breast reconstruction, in order to obtain 
insights that could facilitate improvement in care for both parties.
The final part of this thesis is a general discussion, which entails a chapter based on 
an opinion article (chapter 6) and a summary (chapter 7). This part of the thesis critically 
evaluates what the results of this thesis imply for the counseling of breast cancer patients.
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Chapter 2
Background 
The EuroQol EQ-5D-5L instrument is the most widely-used quality of life measure 
in health economic evaluations. It is unclear whether such a generic instrument 
is valid enough to estimate the benefits of breast reconstruction (BR), given the 
specific changes observed in quality of life after BR. Hence, we aimed to evaluate 
the validity of EQ-5D-5L in patients who had undergone postmastectomy BR.
Methods 
In a 10-year cross-sectional cohort study, 463 mastectomy patients completed 
an online survey: 202 patients with autologous-BR (A-BR), 103 with implant-
based-BR (I-BR), and 158 without BR (MAS). The results were used to evaluate 
the psychometric performance of EQ-5D-5L with respect to the ceiling effect 
and to known-group, convergent, and discriminant validity, by comparing it with 
the Breast-Q, the cancer-specific (EORTC-QLQ-C30), and breast cancer-specific 
(EORTC-QLQ-BR23) questionnaires. 
Results 
EQ-5D-5L was able to discriminate between patients with and without 
complications, MAS with or without BR and MAS versus the general population. 
It was, however, not able to discriminate between A-BR vs. I-BR as well as 
BR vs. general population. It is not clear whether this was due to the insensitivity 
of the instrument, insufficient sample sizes, or because there were no actual 
differences in QoL between these groups. Good convergent and discriminant 
validity of both EQ-5D-5L and its individual dimensions was demonstrated. 
Additional support for the instrument’s validity was revealed by moderate 
correlations between the generic EQ-5D-5L and specific QoL aspects of BR 
such as sexuality and body image. 
Conclusions 
The results of this study support the validity of the EQ-5D-5L as an outcome 






Healthcare budgets are under substantial strain due to increasing healthcare costs. 
Society and insurance companies are progressively confronted with difficult choices about 
which medical interventions are to be reimbursed. Because elective procedures such as 
breast reconstruction (BR) are not life-saving, but primarily aimed at improving quality of 
life, they may be among the first medical interventions to be critically reviewed. Difficult 
decisions about which interventions should be reimbursed can only be made when it is 
possible to reliably compare different medical interventions. The formal way to do this is 
to perform a cost-effectiveness evaluation that makes use of appropriate measures such 
as EQ-5D-5L.
EQ-5D-5L is a widely-used generic health-related quality of life (QoL) instrument, designed 
to measure the most important aspects of health over a broad spectrum of health 
conditions and diseases.1 The instrument is especially used in health economic appraisals 
where comparisons between different therapeutic areas are made when deciding on 
the allocation of resources. In such comparisons the core value of an intervention for 
the patients’ needs to be evaluated, that is the effect of an intervention both on survival 
and quality of life. In economic appraisals survival and quality of life are combined in the 
Quality Adjusted Life Year (QALY). QALYs allow, for example, BR to be compared to an 
intervention in a condition such as diabetes. The QALY is the preferred outcome measure 
in various guidelines for health economic evaluations from national reimbursement 
agencies such as NICE in the U.K..2,3 EQ-5D-5L is specifically designed to measure the 
Q in QALY and is notably different from other questionnaires employed to measure QoL 
as it provides ‘preference-weighted quality of life scores’ (utilities), based on the values of 
the general public. These utilities are needed for the calculation of QALYs. EQ-5D is 
the most widely-used questionnaire in health economic evaluations and is the preferred 
questionnaire of many national reimbursement agencies.2,4 It is therefore important to 
evaluate whether EQ-5D-5L is a valid instrument for the evaluation of QoL in BR patients.
Given the requirement to use appropriate and valid QALY estimates and the increased 
importance of health economic evaluations that provide comparable outcome measures, 
it is relevant for the field of BR surgery to know whether the generic EQ-5D-5L is a valid 
instrument to measure the specific benefits of BR. The present study aimed to evaluate 
the validity of EQ-5D-5L for BR following mastectomy for breast cancer in a large cohort 
of patients with a long follow-up.
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EORTC QLQ-C30 and QLQ-BR23
The EORTC questionnaires are measures for evaluating health-related QoL of cancer 
patients which were designed for use in clinical trials.13 In the present study, the 
cancer-specific QLQ-C30 and the breast cancer-specific QLQ-BR23 questionnaires 
were used. Both have been validated and are widely used in oncology and oncologic 
surgery patients.13-15 The EORTC questionnaires consist of various scales where higher 
scale scores represent higher response levels. This means that a high score on one of 
the functional or QoL scales represents a high level of functioning or QoL, respectively. 
In contrast, a high score on one of the symptom scales indicates a high level of 
problems.13,15
Statistical Methods
Characteristics of the study population were analyzed using descriptive statistics. 
The construct validity of EQ-5D-5L in women who had undergone a postmastectomy 
BR for breast cancer was evaluated. Construct validity is defined as the degree to which 
an instrument measures what it was intended to measure.16 The construct validity of 
EQ-5D-5L was tested by its correlation with other QoL instruments with known validity 
for BR and the ability of the EQ-5D-5L to discriminate between various relevant patient 
groups and outcomes. Three specific forms of construct validity were evaluated.
Distribution of EQ-5D-5L health profiles
The distribution of the responses to the different EQ-5D-5L dimensions and the 
combination of these responses (the health profiles) within individual patients were 
assessed. This provides insight into the sensitivity of the instrument in terms of variance 
in scores on the dimensions and of the number of profiles. It also provides insight about 
a potential ceiling effect. This ceiling effect refers to the common observation that a high 
number of patients report ‘no problems’ on any of the dimensions of EQ-5D. This is often 
considered a psychometric problem, because it may imply an insufficiently sensitive 
questionnaire.16 Hence, we investigated whether BR patients with a perfect health 
score on EQ-5D-5L also showed very good health scores on the Breast-Q well-being 
dimensions. To do this, an aggregated mean score of the Breast-Q ‘psychosocial’, ‘chest 
and upper body’ and ‘abdomen’ well-being scores was calculated for each BR patient.
Known-group validity
The evaluation of known-group validity is based on the idea that distinctively different 
groups should score differently on the measure(s) or instrument(s) under evaluation, in this 
case EQ-5D-5L. Known-group comparisons and hypotheses about the expected effects 
were formulated beforehand and were based on the literature and clinical experience. 
Patients who had not received a BR after mastectomy, had experienced a complication, 
had received radiotherapy, or who were of an older age were hypothesized to have a 
(relatively) lower QoL and therefore a lower score EQ-5D-5L. Patients with an A-BR 
were hypothesized to have a higher QoL and higher EQ-5D-5L scores/values than I-BR 
patients.17,18 EQ-5D-5L outcomes for BR patients were not expected to significantly 
Methods
Patient recruitment
Data were gathered using a cross-sectional online survey sent to patients who in the last 
10 years had been treated for breast cancer at Erasmus MC Cancer Institute in Rotterdam, 
the Netherlands. There were three cohorts of patients who had undergone a mastectomy 
for breast cancer: autologous BR (A-BR), implant-based BR (I-BR), and women who had 
not undergone a BR (MAS). Patients were identified using the hospital’s reimbursement 
administrative system with specific codes for the respective procedures. Patients were 
sent an invitation letter by mail requesting participation in an online survey. Patients 
not proficient in Dutch or who had developed a distant metastasis were excluded. We 
considered including patients with a distant metastasis, but a large proportion of this 
patient group communicated that they did not wish to participate in research on this 
specific topic. Since inclusion of this sub-population was not necessary with respect to 
the aim of the study, these patients were excluded on ethical grounds. Respondents filled 
out an online informed consent form and a series of self-administered questionnaires. 
Non-responders were contacted three weeks later by telephone and asked to consider 




EQ-5D-5L is a standardized measure of health status designed to be a simple and generic 
measure of health-related QoL that can be used in clinical trials and economic evaluations 
of healthcare interventions.9 It has a 5-dimension, 5-level descriptive system, covering the 
dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
It describes 55 = 3125 unique health states, which all have a utility value known from 
previous valuation studies. This utility value is anchored at two points, a value of 1.00 
indicates the value of ‘perfect health’ and 0 equals the value of ‘death’. In accordance 
with economic theory and health economic appraisal guidelines, we used the EQ-5D-5L 
societal utility (value) set specific to the study country, in this case the Netherlands, 
to score the questionnaire and obtain utility values for our sample.2,10,11
Breast-Q
The Breast-Q is a validated patient-reported outcome questionnaire that is widely used in 
the field of breast surgery.12 The modules specifically developed for BR and mastectomy 
were used if applicable. The following five domains of the Breast-Q were used in the 
current study: 1) physical well-being, 2) psychosocial well-being, 3) sexual well-being, 
4) satisfaction with breasts, and 5) satisfaction with the overall outcome. The Breast-Q 
comes with an official score algorithm in the form of the ‘Q-score application’. This 
application was used to transform the questionnaire responses to the respective modules 




Socio-demographic and Clinical Characteristics
The original unmatched cohorts consisted of 202 A-BR, 103 I-BR, and 158 MAS patients 
and showed: a relatively large imbalance in age (with a disproportionate proportion older 
than 70 years in the MAS cohort), laterality of the mastectomy, reconstruction status, 
breast cancer recurrence, chemotherapy and hormone therapy. Table 1 shows the 
socio-demographic and clinical characteristics of both the unmatched and matched 
cohorts of A-BR and I-BR patients in addition to two reference cohorts that were used, 
a MAS cohort and an age-sex matched sample of the general population. The matching 
procedures resulted in a largely balanced cohort, with no statistically significant 
differences between the A-BR and I-BR cohort on the matched pretreatment patient 
characteristics.
differ from Dutch general population reference data. To test this hypothesis, we used the 
raw data from the official Dutch EQ-5D-5L valuation study. This is a large representative 
study with 1000 respondents (505 females) from the general public, which is now used 
as the mandatory reference study for EQ-5D-5L in health economic evaluations in 
the Netherlands.2,10 A skewed EQ-5D-5L distribution score was expected, as EQ-5D-5L 
is a generic quality of life questionnaire and most patients were expected to have few 
side effects by comparison with impact of the BR. Given the expected skewed distribution 
of outcomes, the group comparisons were performed using the non-parametric Wilcoxon 
rank-sum (for 2-group comparisons) and Kruskal-Wallis equality-of-populations rank tests 
(>2-groups).
We performed propensity score matching to control for differences in pretreatment patient 
characteristics in group comparisons directly related to the treatment modality by using 
the PSMATCH3 module for SPSS.19,20 Three consecutive matching procedures were 
performed. First, the A-BR and I-BR cohorts were matched on pretreatment clinical and 
socio-demographic characteristics (Table 1). Subsequently, MAS was matched with the 
combined matched BR cohort on clinical characteristics, because socio-demographic 
characteristics were not available for all patients in this cohort. Finally, the Dutch general 
population reference sample was age and sex matched to the combined matched 
BR and MAS cohorts.
Convergent and Discriminant Validity
Convergent validity is based on the idea that items or scales that measure a similar 
concept should be strongly correlated to each other, whereas other items or scales that 
measure concepts that are unrelated should have a weak correlation to one another, 
which indicates discriminant validity. The convergent and discriminant associations were 
hypothesized beforehand and were assessed using non-parametric Spearman rank 
correlation coefficients. The following criteria for correlation strength, as formulated by 
Cohen, were utilized: weak for 0.1 ≤ rs < 0.3, moderate for 0.3 ≤ rs < 0.5 and strong for 
rs ≥ 0.5.21 For statistical testing, two-sided p-values ≤ 0.05 were considered statistically 






    Unmatched cohort    Matched cohorts   
     A-BR I-BR MAS D-GP  A-BR I-BR MAS D-GP
  N 202 103 158 505  67 67 134 268
Age, median (SD)   55a (9.28) 53a,c (12.22) 63b (11.94) 47a,b (17)  55a (9.49) 55a (11.63) 61b (10.97) 58a,b (11)
Year of BC diagnosis, median (SD)   2008a (5.23) 2007a (6.64) 2003b (7.95) N/A  2007a (6.27) 2006a,b (7.26) 2003b (7.85) N/A
Year of mastectomy, median (SD)   2008a (4.84) 2007a (6.31) 2006b (6.35) N/A  2008a (6.19) 2007a (6.87) 2007a (5.74) N/A
Year of first BR, median (SD)  2011a (4.29) 2009a (7.18) 2010a,b (11.38) N/A  2010a (5.77) 2009a (6.66) 2014a (2.13) N/A
Year of last BR, median (SD)   2013a (2.89) 2012a (3.51) 2015a (1.15) N/A  2013a (2.78) 2012a (4.21) 2015a (1.15) N/A
Laterality mastectomy             
 Unilateral   179a (88.6%) 48b (46.6%) 71a (83.5%) N/A  46a (68.7%) 47a (70.1%) 64a (85.3%) N/A
 Bilateral   23a (11.4%) 55b (53.4%) 14a (16.5%) N/A  21a (31.3%) 20a (29.9%) 64a (85.3%) N/A
Reconstruction status             
 Unilateral BR   175a (86.6%) 46b (44.7%) 1c (1.2%) N/A  44a (65.7%) 45a (67.2%) 0 (0.0%) N/A
 Bilateral BR   26a (12.9%) 56b (54.4%) 0 (0.0%) N/A  22a (32.8%) 22a (32.8%) 0 (0.0%) N/A
 Previously had a BR  1a (0.5%) 1a (1.0%) 9b (10.6%) N/A 1a (1.5%) 0 (0.0%) 8b (10.7%) N/A
 Never had BR and doesn’t want BR   0 (0.0%) 0 (0.0%) 70a (82.4%) N/A  0 (0.0%) 0 (0.0%) 61a (81.3%) N/A
 Never had BR but wants BR   0 (0.0%) 0 (0.0%) 5a (5.9%) N/A  0 (0.0%) 0 (0.0%) 5a (6.7%) N/A
Patient reported complications             
 None   106a (52.5%) 46a (44.7%) 6b (3.8%) N/A  37a (55.2%) 34a (50.7%) 4b (3.0%) N/A
 Yes   80a (39.6%) 47a (45.6%) 7b (4.5%) N/A  24a (35.8%) 26a (38.8%) 7b (5.3%) N/A
 N/A  16a (7.9%) 10a (9.7%) 144b (91.7%) N/A 6a (9.0%) 7a (10.4%) 122b (91.7%) N/A
Breast Cancer Recurrence            
 No recurrence   183a (90.6%) 82b (79.6%) 122b (77.2%) N/A  57a (85.1%) 55a (82.1%) 101a (75.4%) N/A
 Local recurrence   10a (5.0%) 13b (12.6%) 21b (13.3%) N/A  7a (10.4%) 8a (11.9%) 19a (14.2%) N/A
 Distant recurrence   9a (4.5%) 8a (7.8%) 15a (9.5%) N/A  3a (4.5%) 4a (6.0%) 14a (10.4%) N/A
Chemotherapy             
 Yes   139a (68.8%) 52b (50.5%) 98a,b (62.0%) N/A  40a (59.7%) 33a (49.3%) 82a (61.2%) N/A
 No   63a (31.2%) 51b (49.5%) 60a,b (38.0%) N/A  27a (40.3%) 34a (50.7%) 52a (38.8%) N/A
Radiotherapy             
 Yes   74a (36.6%) 27a (26.2%) 84b (53.2%) N/A  16a (23.9%) 19a (28.4%) 64b (47.8%) N/A
 No   128a (63.4%) 76a (73.8%) 74b (46.8%) N/A  51a (76.1%) 48a (71.6%) 70b (52.2%) N/A
Hormone therapy             
 Currently undergoing treatment   49a (24.3%) 18a (17.5%) 58b (36.7%) N/A  13a (19.4%) 11a (16.4%) 40a (29.9%) N/A
 Treated   66a (32.7%) 21a,b (20.4%) 22b (13.9%) N/A  20a (29.9%) 14a (20.9%) 21a (15.7%) N/A
 Not treated   87a (43.1%) 64b (62.1%) 78a,b (49.4%) N/A  34a (50.7%) 42a (62.7%) 73a (54.5%) N/A
Employment status             
 Yes, outdoor  117a (60.3%) 61a (64.2%) N/A N/A  43a (68.3%) 41a (67.2%) N/A N/A
 Yes, inhome   19a (9.8%) 8a (8.4%) N/A N/A  3a (4.8%) 6a (9.8%) N/A N/A
 No   58a (29.9%) 26a (27.4%) N/A N/A  17a (27%) 14a (23.0%) N/A N/A
Participation in social activities             
 Rarely   16a (8.2%) 8a (8.2%) N/A N/A  5a (7.8%) 4a (6.5%) N/A N/A
 Average   112a (57.1%) 49a (50.0%) N/A N/A  35a (54.7%) 28a (45.2%) N/A N/A
 Often   68a (34.7%) 41a (41.8%) N/A N/A  24a (37.5%) 30a (48.4%) N/A N/A
Living arrangement             
 1 person household   30a (15.5%) 19a (19.2%) N/A N/A  14a (22.2%) 14a (22.2%) N/A N/A
 Multiperson househol   164a (84.5%) 80a (80.8%) N/A N/A  49a (77.8%) 49a (77.8%) N/A N/A
Children in household             
 Yes   103a (52.8%) 50a (51.0%) N/A N/A  36a (56.3%) 27a (42.9%) N/A N/A
 No   92a (47.2%) 48a (49.0%) N/A N/A  28a (43.8%) 36a (57.1%) N/A N/A
Education             
 Elementary school   0 (0.0%) 2a (2.1%) N/A N/A  0 (0.0%) 2a (3.2%) N/A N/A
 Lower-level profesional schooling   31a (16.3%) 10a (10.3%) N/A N/A  4a (6.5%) 6a (9.5%) N/A N/A
 Mid-level highschool   44a (23.2%) 19a (19.6%) N/A N/A  15a (24.2%) 13a (20.6%) N/A N/A
 Mid-level profesional schooling   41a (21.6%) 21a (21.6%) N/A N/A  14a (22.6%) 12a (19.0%) N/A N/A
 Upper-level highschool   23a (12.1%) 16a (16.5%) N/A N/A  6a (9.7%) 9a (14.3%) N/A N/A
 Higher-level professional schooling   35a (18.4%) 22a (22.7%) N/A N/A  15a (24.2%) 15a (23.8%) N/A N/A
 Academic schooling   16a (8.4%) 7a (7.2%) N/A N/A  8a (12.9%) 6a (9.5%) N/A N/A
Values in the same row and sub-table 
not sharing the same superscript are 
significantly different at p< .05 in the 
two-sided test of equality for column 
proportions. Cells with no superscript 
are not included in the test. BR (breast 
reconstruction), A-BR (autologous BR), 
I-BR (implant BR), MAS (mastectomy not 
followed by BR), D-GP (Dutch age-sex 
matched reference population). A-BR, 
I-BR and MAS cohorts were propensity 
score matched. D-GP cohort was age-
sex matched.
Table 1. Sociodemographic and clinical characteristics of patient samples
Distribution of EQ-5D-5L Health Profiles
Figure 1 illustrates the distribution of responses to the individual dimensions for all samples. 
One-to-one comparisons between the matched BR cohorts (i.e. A-BR and I-BR) did not 
show statistically significant differences on any of the EQ-5D-5L dimensions. Comparisons 
between the BR and Dutch general population (D-GP) cohorts on the individual dimensions 
also showed no statistically significant differences. Finally, comparisons between the BR 
and MAS cohorts showed substantial differences which were statistically significant for the 
‘mobility’ and ‘usual activities’ dimensions (both p<.001).
Table 2 depicts the most frequently occurring EQ-5D-5L health profiles in the different 
cohorts and allows the evaluation of a potential ceiling effect. The unmatched cohorts are 
presented in this table because comparisons are made within and not between patient 
groups. In total, 69 unique health profiles were reported in the BR cohorts. Thirty-one 
percent of A-BR patients and 35% of I-BR patients reported no problems on any of the 
five dimensions (health profile 11111), making it the most frequent health profile in these 
cohorts, similar to that of the D-GP. This ceiling effect was less pronounced among MAS 
patients where 24.7% reported perfect health in the unmatched cohort. To further explore 
this ceiling effect, an aggregated mean score of the Breast-Q ‘psychosocial’, ‘chest and 
upper body’ and ‘abdomen’ well-being scores was calculated for each BR patient. 
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Table 2. Most frequently occurring EQ-5D-5L Health Profiles in unmatched BR cohorts
Health profile A-BR I-BR MAS D-GP
11111 63 (31.2%) 36 (35%) 39 (24.7%) 179 (35.4%)
11121 25 (12.4%) 9 (8.7%) 10 (6.3%) 63 (12.5%)
11112 12 (5.9%) 8 (7.8%) 9 (5.7%) 19 (3.8%)
11221 12 (5.9%) 5 (4.4%) 6 (3.8%) 21 (4.2%)
11122 11 (5.4%) 8 (7.8%) 5 (3.2%) 15 (3%)
11131 7 (3.5%) 3 (2.9%) 3 (1.9%) 7 (1.4%)
11222 3 (1.5%) 3 (2.9%) 4 (2.5%) 5 (1%)
21121 3 (1.5%) 2 (1.9%) 2 (1.3%) 5 (1.6%)
Figure 1. EQ-5D-5L responses in matched samples of A-BR (n=67) I-BR (n=67) and MAS
patients (n=134) and Dutch general population (n=268)
Health profile denoting the respective level of the following dimensions in the order:
Mobility, Self-Care, Usual Activities, Pain/ Discomfort, Anxiety/ Depression. 1 “no problems” up to 
5 “severe problems/unable to”. All health profiles that occurred five or more times in the unmatched 
BR cohort are listed. BR (breast reconstruction), A-BR (autologous BR), I-BR (implant BR), MAS 
(mastectomy not followed by BR), D-GP (Dutch age-sex matched reference population).
All comparisons were tested using Kruskal-Wallis equality-of-populations rank test. A-BR (autologous 
breast reconstruction), I-BR (implant breast reconstruction), MAS (mastectomy not followed by breast 
reconstruction), D-GP (Dutch age-sex matched reference general population). A-BR, I-BR and MAS 
cohort were propensity score matched. D-GP cohort was age-sex matched. (Stolk, 2016)
Known-group Validity
The findings above were based on the dimensions and profiles of the EQ-5D-5L, attributes 
common to QoL questionnaires. A key feature of EQ-5D-5L is the utility score, which can 
be used in economic evaluations. The results based on this utility score are presented in 
an overview of the known-group comparisons in Table 3. Contrary to our hypothesis, no 
statistically significant differences between the A-BR and I-BR patient groups were found 
using EQ-5D-5L utility scores. As hypothesized, BR yielded a statistically significant better 
QoL compared to MAS. Breast cancer patients who had undergone a BR did not show a 
statistically significant different QoL compared to the D-GP. Patients who had experienced 
a complication following BR reported a statistically significant lower mean QoL than 
patients who had not experienced a complication. 
We found that over three quarters of BR patients with an EQ-5D-5L score of 1.00 had an 
aggregated Breast-Q score of 80 or higher compared to only 22 percent of BR patients that 
had an EQ-5D-5L score lower than 1.00. This suggests that the ceiling effect on EQ-5D-5L 
represented patients that indeed experienced very few or no problems with regard to 
their BR-related well-being and consequently did not necessarily represent insensitivity of 
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Table 3. Known-group comparisons
    EQ-5D-5L    
Age *   Count Mean Standard Deviation p-value 
 <50   387 .867 .17 .87 
 50-60  244 .839 .18    
 60-70  222 .831 .18    
 >70   115 .786 .20   
Cohorts        
 BR   305 .844 .18    
 BR (matched) 134 .863 .16    
  A-BR 202 .840 .18    
  A-BR (matched) 67 .872 .14    
  I-BR 103 .851 .17    
  I-BR (matched) 67 .853 .18    
 MAS  158 .792 .20    
 MAS (matched) 134 .798 .20    
 D-GP  268 .841 .16    
   A-BR v I-BR    .89 (matched .70) 
   BR v MAS    .00 (matched .00) 
   BR v GP    .49 (matched .15) 
   MAS v GP    .01 (matched .03) 
   All groups    .00 (matched .00) 
Patient reported complications *    .00 
 None  152 .872 .16    
 Yes   127 .806 .19   
Reconstruction status *    .56 
 Unilateral BR 222 .836 .19    
 Bilateral BR 82 .859 .15   
Radiotherapy *    .06 
 Yes   101 .857 .19   
 No   204 .837 .17   
Table 4. Convergent and discriminant validity between EQ-5D-5L dimensions, EQ-5D-5L 
and other quality of life measures.
All comparisons were tested using Kruskal-Wallis equality-of-populations rank test. Matched 
(propensity score matched), BR (breast reconstruction), A-BR (autologous BR), I-BR (implant BR), 
MAS (mastectomy not followed by BR), D-GP (Dutch age-sex matched reference population). 
The group comparisons marked with * were performed on the unmatched BR cohort. The outcome 
values in this table are based on a sample from an academic hospital, may not be representative for 
the BR population as a whole, and are solely illustrative of the ability of EQ-5D-5L to detect differences 
between relevant groups. Hence, these outcomes should not be used as EQ-5D-5L reference values 
in scientific studies.     
Only scales with at least one correlation of moderate strength (0.35-0.50) or higher are shown. 
Correlations that were hypothesized to show a convergent correlation are highlighted in dark grey 
with a fine border. Correlations that were hypothesized to show a discriminant correlation are 
highlighted in light grey with a thick border. Correlations of moderate strength (0.35-0.50) are printed 
in italics, strong correlations (>0.50) are in bold. ** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed).
Convergent and Discriminant Validity
Table 4 shows the correlations of moderate strength or higher between the QoL of 
EQ-5D-5L and its individual dimensions on the one hand, and the Breast-Q scales and 
EORTC scales for the unmatched BR cohorts on the other. Predefined hypotheses 
about convergence and divergence of correlations were used to assess validity and are 
depicted in Table 4. 
Breast-Q condition-specific QoL-measure      
Psychosocial Well-being -.288** -.250** -.335** -.390** -.501** .524**
Sexual Well-being -.223** -.249** -.249** -.240** -.417** .401**
Physical Well-being:  
Chest and Upper Body -.204** -.249** -.409** -.561** -.266** .516**
Physical Well-being:  
Abdomen -.322** -.191** -.427** -.474** -.228** .484**
EORTC QLQ-C30 cancer-specific QoL-measure      
Global health status/QoL -.332** -.291** -.443** -.464** -.414** .553**
Physical Function -.555** -.274** -.613** -.505** -.269** .599**
Role Function -.428** -.266** -.690** -.606** -.276** .634**
Emotional Function -.188** -.237** -.378** -.382** -.614** .547**
Cognitive Function -.213** -.250** -.352** -.353** -.339** .414**
Social Function -.290** -.246** -.465** -.383** -.389** .497**
Fatigue .329** .250** .530** .522** .384** -.595**
Pain .460** .294** .627** .744** .279** -.704**
Insomnia .290** .133* .398** .412** .308** -.465**
Appetite loss .168** .220** .336** .301** .317** -.375**
EORTC QLQ-B23 breast cancer-specific QoL-measure     
Body image -.222** -.218** -.313** -.299** -.395** .430**
Future perspective -.199** -.239** -.295** -.288** -.485** .442**
Systemic therapy .262** .248** .400** .384** .287** -.458**
Breast symptoms .231** .235** .355** .478** .188** -.435**
Arm symptoms .235** .284** .490** .499** .190** -.485**
Known-group Validity
A-BR vs I-BR
Currently, the only utilities available that differentiate between different BR techniques were 
obtained through expert opinion interviews with plastic surgeons, generally considered 
an inappropriate method for eliciting such values.5-7 In these studies surgeons estimated 
that A-BR resulted in the highest utility (0.83) followed by I-BR (0.66) and mastectomy 
not followed by BR (0.63).17,18 However, in the known-group comparison no significant 
differences were found on the EQ-5D-5L between A-BR or I-BR in either the matched or 
unmatched cohorts. Since previous utility studies used controversial methods, it is difficult 
to determine whether EQ-5D-5L was unable to detect differences between A-BR and 
I-BR because there were no substantial differences in QoL or because of lack of sensitivity 
of the measure. As EQ-5D-5L also showed convergent associations with the reference 
measures on 4 out of 5 dimensions, we consider the former more likely.
BR vs MAS
EQ-5D-5L was able to discriminate between BR and MAS patients both in an uncorrected 
and a matched cohort. Patients who had received a BR after their mastectomy had 
significantly better EQ-5D-5L scores than patients who had not received a BR. This result 
corresponds with the findings of previous studies which also reported better QoL of BR 
patients compared to MAS patients, but conflicts with other studies that show little to 
no difference.22-27 It appears that more recent studies have been more successful in finding 
significant differences between both patient groups, especially when making use of the 
Breast-Q questionnaire. This may be due to improved surgical techniques, improved 
sensitivity of QoL instruments, or a significant difference between groups may after all 
not exist. A systematic review or a meta-analysis comparing the QoL of MAS vs BR could 
help inform us of the true effect on QoL of BR.
Complications vs no complications after BR
As hypothesized, patients who had experienced complications following their BR had a 
poorer mean QoL assessed with EQ-5D-5L.
Convergent and Discriminant Validity
The EQ-5D-5L dimensions ‘mobility’, ‘usual activities’, ‘pain/discomfort’, and ‘anxiety/ 
depression’ showed strong correlations with the domains and scales of similar concepts on 
both the BR-specific Breast-Q and EORTC cancer and breast cancer specific measures, 
which implies good convergent validity of EQ-5D-5L for BR. These correlations were 
considerably higher than those with dissimilar dimensions, which indicates good discriminant 
validity of EQ-5D-5L for BR. The EQ-5D-5L dimension ‘self-care’ showed only weak 
correlations with the other measures, which is probably explained by a lack of variance: the 
vast majority of BR patients (94.3%) reported no problems on this dimension. This result 
was also seen in the age- and sex-matched Dutch general population (Figure 1). 
Most scales relevant to BR surgery showed at least moderate correlation with EQ-5D-5L. 
A notable exception to this finding were the dimensions of the Breast-Q that measured 
patient satisfaction with either the breast or outcome, because they showed weak 
correlations with EQ-5D-5L (r=0.345 and r=0.327, respectively).
Discussion
This is the first study to evaluate the validity of EQ-5D-5L in patients who received a BR 
after having undergone a mastectomy for the treatment of breast cancer. Evaluation of the 
validity of this outcome measure is important as EQ-5D-5L is currently the preferred QoL 
outcome measure in cost-effectiveness evaluations that inform healthcare policymakers and 
reimbursement agencies. EQ-5D-5L was able to discriminate between several, but not all, 
patient groups and outcomes. Good convergent and discriminant validity of both 
EQ-5D-5L and its individual dimensions was demonstrated. Furthermore, additional 
support for validity was revealed by moderate correlations between the generic EQ-5D-5L 
and specific QoL aspects of BR like such as sexuality and body image.
Distribution and ceiling effect of EQ-5D-5L health profiles
One aspect on which the discriminative ability of a measure is frequently judged, is its 
ability to detect differences between a given sample/cohort and the general population.16 
However, there was a large resemblance in the distribution of EQ-5D-5L responses to the 
EQ-5D-5L of patients who had received a BR and that of the age-sex matched cohort 
of the Dutch general population, with no statistically significant differences. Normally 
speaking, these findings would limit the validity of the outcome measure. However, in 
the case of BR this may not necessarily be the case. Given that the overall aim of BR 
is to restore the QoL of breast cancer patients to a level comparable with that before 
they were afflicted by breast cancer, and that women eligible for a BR may represent a 
relatively healthy patient group, outcomes comparable to the general population could be 
expected and were, indeed, hypothesized in this study. Further analysis of the distribution 
of responses (Figure 1 and Table 3) showed that EQ-5D-5L can detect statistically 
significant differences between BR and MAS patients on both the ‘mobility’ and ‘usual 
activities’ EQ-5D-5L dimensions, indicating sensitivity of the instrument. In our BR-cohort 
a considerable ceiling effect was found which can be considered a psychometric 
problem in terms of sensitivity.16 EQ-5D dimensions might not tap into the relevant 
dimensions of QoL following BR, benefits of BR might go undetected, and the (cost-) 
effectiveness of BR would thus be underestimated. However, a ceiling effect may only 
represent a problem if it meant that the instrument is insensitive to problems actually 
present in the sample at hand. We found that the EQ-5D-5L ceiling effect represented 
patients that did indeed experience very few or no problems with respect to their 
BR-related well-being. Hence, we believe that the ceiling effect does not present a major 
problem in calculating a valid cost-effectiveness ratio in economic evaluations of BR.
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There are two important aspects of QoL in relation to BR, assessed by the Breast-Q 
and EORTC-BR23, that are worth highlighting since EQ-5D-5L is potentially insensitive 
to these features, namely ‘sexuality’ and ‘body image’.28,29 Both had correlations of 
moderate strength with the ‘anxiety/depression’ scale.
Conclusions
EQ-5D-5L was able to discriminate between various relevant patient groups and 
outcomes. It was not able, however, to discriminate between A-BR vs I-BR and BR 
vs general population. Convergent and discriminant validity of both the individual 
EQ-5D-5L dimensions and of EQ-5D-5L was demonstrated by strong correlations with 
measures employing similar concepts. Furthermore, EQ-5D-5L showed correlations 
of moderate strength with QoL aspects important to BR patients: sexuality and body 
image. In conclusion, EQ-5D-5L showed sufficient validity to be used as one of the 
primary outcome measures in the evaluation of QoL outcomes in patients who have 
undergone a postmastectomy BR for breast cancer treatment. The next step will be to 
obtain representative EQ-5D-5L reference values for this patient population.
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Chapter 3
Background 
Differences in health-related quality of life (HRQoL)-outcomes after different 
surgical breast cancer treatment options, including breast reconstruction (BR), 
are relevant for counseling individual patients in clinical decision-making, and for 
(societal) evaluations such as (cost-) effectiveness analyses. However, current 
literature shows contradictory results, due to use of different Patient-Reported 
Outcome Measures (PROMs) and study designs with limited patient numbers. 
Therefore, this article sets out to improve this evidence from a clinical and 
societal perspective using PROMs in a large, cross-sectional study for different 
surgical breast cancer treatment options.
Methods 
HRQoL was assessed through the EQ-5D-5L, EORTC-QLQ-C30/-BR23 and 
Breast-Q. Patients with different treatments (breast conserving surgery (BCS), 
mastectomy (MAS), autologous BR (A-BR), implant-based BR (I-BR)) were 
compared after propensity-weighted adjustment of pre-treatment differences. 
The EQ-5D was used to value the effect of surgical complications. 
Results 
1871 breast cancer patients participated (BCS: n=615, MAS: n=507, A-BR: 
n=330, I-BR: n=419). MAS-patients reported the lowest mean HRQoL based on 
the EQ-5D (MAS:0.805, BCS:0.844, A-BR:0.849, I-BR:0.850) and functioning 
scores of the EORTC-QLQ-C30. Based on the Breast-Q, A-BR-patients had 
higher mean satisfaction with outcome and satisfaction with breasts and had 
higher sexual well-being scores than I-BR patients. Patients with complications 
(except for I-BR) reported statistically significant lower HRQoL than patients 
without complications. Complications in A-BR patients resulted in a substantially 
lower HRQoL than in I-BR patients. 
Conclusions 
Our study shows the added value of breast conservation and reconstruction 
compared to mastectomy, however, differences between BCS, I-BR, and A-BR 






Because five-year survival rates for early stage breast cancer are relatively high,1,2 the 
effects of breast cancer and its treatment on quality of life become more important, which 
may affect surgical decision-making. Since mastectomy (MAS) and breast conserving 
surgery (BCS) including radiotherapy have similar disease-free and overall survival,3-5 the 
effects of different treatment modalities on outcomes other than survival gain significance. 
Because loss of a breast may negatively affect psychosocial health, body image, and 
sexual function,6 guidelines recommend that the possibility of breast reconstruction 
(BR) should be discussed with every patient scheduled for MAS.7-9 Multiple options are 
available, either using autologous tissue (autologous BR, A-BR) or breast implants 
(implant BR, I-BR), varying in costs, timing, duration, complication rates, and cosmetic 
results.6,10,11 BR aims to improve the patient’s well-being and health-related quality of life 
(HRQoL),6,10 but patients opting for BR also have a risk of complications,12-15 reconstruction 
failure,12,13 or disappointing (cosmetic) results.6 Consequently, shared decision-making 
(SDM) between physicians and patients about the preferred surgical treatment is a 
complex trade-off between outcomes and risks.
HRQoL-outcomes after different surgical breast cancer treatment options are relevant for 
counseling individual patients in clinical decision-making, and for societal evaluations as 
cost-effectiveness analyses used in health policy. Research shows that post-treatment 
HRQoL is relatively high in breast cancer patients, but evidence about (differences in) 
HRQoL after different treatment options is conflicting.16-19 This conflicting evidence may 
be explained by variation in the use of patient-reported outcome measures (PROMs), 
study designs, and patient populations. For instance, there are both studies that have 
and have not found differences in HRQoL between patients who had undergone BCS or 
MAS.20 Also, several higher quality studies did not find statistically significant differences in 
HRQoL, body image, and sexuality between patients with or without BR.21 We believe that 
evidence should be improved, as such information is relevant for choosing a treatment in 
clinical decision-making and for health policy. Until now, outcomes have been generally 
measured in small, cross-sectional, mono-center studies. Ideally, one would include all 
surgical options relevant to breast cancer patients in one large prospective cohort study.21 
Santosa et al. performed such a large prospective study, comparing patients with I-BR 
and A-BR.22 Furthermore, outcomes measured over a longer period of time would be 
of interest, as different surgical outcomes may have a different HRQoL-course over time. 
For example, recovery from surgical complications will take additional time.
To improve the evidence on the impact of breast cancer surgery and consequently for 
clinical decision-making and health policy, the present study aimed to compare HRQoL 
outcomes for four common surgical breast cancer treatment options (BSC, MAS, A-BR, 
I-BR). HRQoL was assessed using multiple PROMs in a large, multicenter, retrospective, 
cross-sectional cohort of breast cancer patients up to ten years after diagnosis. The 
second aim was to investigate the impact of complications on HRQoL following these 
different surgical treatment options. We hypothesized that BCS and A-BR are favorable 
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Breast-Q. A treatment-specific PROM, developed to measure breast-related QoL and 
satisfaction, on several HRQoL domains. Six postoperative domains were used from the 
different modules which were developed for the respective patient groups: ‘Satisfaction 
with Breasts’, ‘Satisfaction with Outcome’, ‘Psychosocial Well-being’, ‘Sexual Well-being’, 
‘Physical Well-being Chest’, ‘Physical Well-being Abdomen’. The raw scores of the 
Breast-Q domains were converted to scores between 0 (worst) and 100 (best) using the 
Q-score software.27 
Analyses
Twenty-five patients did not report their highest completed education level; these 
missing answers were imputed using a single imputation method. A propensity-score 
weighting for multiple treatments was calculated according to the method of McCaffrey 
et al.28 to adjust for covariates that predict receiving either one of the four surgical 
treatment options, thereby reducing the effects of confounding. The following clinical and 
sociodemographic characteristics were included in the propensity weight calculation: 
age at time of survey, education, year of breast cancer diagnosis, year of surgery, 
chemotherapy, hormone therapy, and breast cancer recurrence. The EQ-5D Dutch 
general population reference sample (GP) was matched to all surgical groups using age 
and sex as the matching variables. Propensity weights were calculated by the Toolkit 
for Weighting and Analysis of Non-equivalent Groups (TWANG) Package for STATA.29
For all responding patients, propensity-adjusted patient and treatment characteristics and 
HRQoL were presented. Propensity weights were incorporated in the analyses using the 
Stata-SE14 survey (svy) post-estimation function.30 Mean scores, confidence intervals, 
and pair-wise comparisons were subsequently obtained and performed using the margins 
regression estimation function. Column proportions were chi-squared tested. The utilities 
resulting from the EQ-5D per surgical treatment were stratified by experienced surgical 
complications. Utilities per surgical treatment were plotted over the course of time in 
three-year intervals (≤3; 3≤6; 6≤9; >9), starting at time of last BR.
For statistical testing, two-sided p-values ≤0.05 were considered statistically significant. 
All analyses were performed in StataCorp Stata-SE14.31
Results 
1,871 out of 3,804 patients (49%) responded, consisting of 615 BCS, 507 MAS, 330 A-BR, 
and 419 I-BR patients. Table 1 presents patient and treatment characteristics. Nearly 
all A-BR procedures were abdominally-based free-flap reconstructions. After propensity-
weighted adjustment, estimated group sizes were reduced to 434.0 BCS, 386.3 MAS, 
178.6 A-BR, and 295.5 I-BR patients. Group sizes declined as patients with certain 
characteristics from one group occurred less frequently in another group, and thus 
received a relative score weight lower than 1. After propensity-weighted adjustment, 
balance was achieved for all variables, except for age and chemotherapy treatment.
over I-BR and MAS in terms of HRQoL, however, in the absence of complications, with 
MAS yielding the least preferable outcomes.
Methods
Study population
Female breast cancer patients (n=3,804) from four hospitals in the Netherlands (one 
academic hospital, three general hospitals) were invited by mail to participate in a self-
administered cross-sectional online survey. Patients were included if they had been 
surgically treated for non-metastatic breast cancer in the last ten years (2008-2018). 
Patients who had developed distant metastases since curative treatment or who were 
not proficient in Dutch were excluded. Four groups were formed based on the surgical 
procedure: BCS, MAS, A-BR, or I-BR. Time between surgery and invitation was over 
6 months, to ensure patients had recovered from the treatment. Patients who preferred 
completing a paper questionnaire, were sent one on request. Respondents gave informed 
consent for processing their coded survey results. The Medical Ethics Committee of the 
Erasmus MC reviewed and approved the study protocol (MEC-2015-273).
Measures
The survey included questions regarding baseline patient and treatment characteristics, 
including surgical complications, and the following validated questionnaires:
EQ-5D-5L. This questionnaire of health status measures problems in five dimensions 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), all with five 
levels of severity (no, slight, moderate, severe, and extreme problems). Per health state, 
a ‘value’ can be assigned, where 0.00 and 1.00 represent the value for death and perfect 
health, respectively. This ‘value’ is also referred to as utility, index score, or preference. 
The EQ-5D includes values of the general public in the valuation of HRQoL, resulting in 
‘preference-weighted QoL scores’, often referred to as ‘utilities’. Utilities are used as 
outcomes in economic evaluations, which can inform health policy. A mean general 
population (GP) reference was obtained to compare study results to that of a sample of 
the Dutch general population.23
EORTC QLQ-C30/BR23. The EORTC Quality of Life Questionnaires (QLQ) measures 
HRQoL in cancer patients,24 the breast cancer-specific QLQ-BR23 supplements the 
cancer-specific QLQ-C30.25 Both consist of functioning and symptom scales; the 
QLQ-C30 also includes a global health status scale. All items and scales range from 0 to 
100, with higher scores presenting a higher level of functioning or general health for the 
functional and global health status scales, respectively, and higher scores representing 





    Groups before propensity-weighted adjustment   Groups after propensity-weighted adjustment   
     BCS MAS A-BR I-BR  BCS MAS A-BR I-BR
Group size (n)  615 507 330 419 434 386.3 178.6 295.5
Time variables, mean (SD)     
Age (in years) at time of survey X*  64.43 (9.07)a,b  65.90 (10.67)a 56.35 (9.17)b 55.79 (10.44)b 62.95 (9.67)a 62.23 (10.37)a 59.58 (9.72)b 60.05 (9.96)b
Time (in years) between MAS/BCS - survey X 6.14 (3.90)a 7.28 (4.97)b 7.87 (5.18)b 7.65 (5.75)b 7.04 (4.56)a 6.86 (4.34)a 6.61 (4.65)a 7.04 (4.95)a
Time (in years) between BR - survey  N/A N/A 5.67 (4.76)a 6.20 (5.20)a N/A N/A 4.93 (4.34)a 5.75 (4.54)b
Time (in years) between last BR surgery - survey N/A N/A 4.54 (4.34)a 4.53 (3.67)a N/A N/A 4.01 (3.78)a 4.48 (3.32)a
Treatment characteristics          
Reconstruction status1          
 Unilateral BR  N/A N/A 85.6% 64.2% N/A N/A  85.4% 71.1%
 Bilateral BR  N/A N/A 14.4% 35.8% N/A N/A  14.6% 28.9%
 Previously had a BR  N/A 7.8% N/A N/A N/A 8.7% N/A N/A
 Never had BR and does not want BR  N/A 87.4% N/A N/A N/A 84.9% N/A N/A
 Never had BR but wants BR  N/A 4.6% N/A N/A N/A 6.4% N/A N/A
Timing of reconstruction1          
 Immediate BR  N/A N/A 15.9% 46.1% N/A N/A 15.6% 47.6%
 Delayed BR  N/A N/A 83.0% 53.5% N/A N/A 82.6% 52.0%
Laterality of MAS           
 Unilateral  N/A 85.6% 87.9% 67.1% N/A 86.1% 89.9% 74.4%
 Bilateral  N/A 14.4% 12.1% 32.9% N/A 13.9% 10.2% 25.6%
Recurrence X          
 No recurrence  93.8% 85.8% 90.9% 89.3% 90.1% 91.0% 91.4% 90.9%
 Local recurrence  1.1% 7.7% 5.5% 5.7% 3.5% 4.1% 4.0% 4.5%
 Distant recurrence  5.0% 6.5% 3.6% 5.0% 6.4% 4.9% 4.6% 4.5%
Patient-reported complications          
 No complication  84.2% 63.5% 56.7% 66.5% 82.3% 64.6% 53.4% 68.4%
 Complication   15.8% 22.4% 43.3% 33.5% 17.7% 21.5% 46.6% 31.6%
 Unknown  0.0% 14.1% 0.0% 0.0% 0.0% 13.9% N/A N/A
Number of comorbidities          
 No comorbidities  47.3% 42.2% 51.8% 52.7% 47.1% 48.2% 49.8% 48.7%
 1 comorbidity  32.5% 35.3% 30.9% 34.8% 32.6% 34.3% 12.6% 36.4%
 2 comorbidities  14.5% 16.6% 12.4% 8.1% 15.0% 13.2% 32.9% 9.4%
 3 or more comorbidities  5.7% 5.9% 4.8% 3.9% 4.5% 4.3% 4.7% 4.3%
Treated with:          
 Chemotherapy X  24.2% 44.2% 63.9% 48.4% 37.4% 42.7% 47.6% 43.9%
 Radiotherapy  94.3% 36.9% 35.8% 24.1% 94.9% 33.0% 30.6% 22.6%
 Hormone therapy X          
 Yes, still receiving treatment  19.0% 24.7% 29.1% 24.1% 58.2% 56.3% 57.2% 58.8%
 Yes, completed  67.5% 50.3% 48.5% 56.8% 23.8% 23.4% 22.2% 21.6%
Patient characteristics          
Highest completed education X          
 Lower level   24.9% 28.8% 18.2% 14.6% 24.0% 23.4% 21.5% 18.1%
 Mid-level   55.1% 48.1% 56.1% 55.8% 54.5% 53.6% 52.7% 55.3%
 High-level professional schooling  20.0% 23.1% 25.8% 29.6% 21.5% 23.1% 25.8% 26.6%
Employment status          
 Employed outside home  30.7% 23.5% 54.8% 58.0% 35.3% 31.6% 45.6% 45.6%
 Employed from home  1.8% 5.7% 7.9% 4.1% 1.6% 5.1% 10.2% 3.6%
 Not employed  52.8% 59.6% 33.0% 32.2% 49.0% 52.4% 37.1% 42.8%
 Other  14.6% 11.2% 4.2% 5.7% 14.1% 10.9% 7.2% 8.0%
Household composition          
 One person household  19.3% 22.7% 17.6% 15.0% 17.9% 18.8% 22.7% 19.9%
 Multi person household  80.7% 77.3% 82.4% 85.0% 82.1% 81.2% 77.4% 80.1%
Relationship status          
 Single  7.6% 7.7% 10.9% 9.1% 7.8% 9.2% 9.6% 8.7%
 Married  77.9% 74.2% 77.3% 78.3% 79.0% 76.6% 73.5% 76.6%
 Divorced  3.6% 4.1% 5.2% 7.4% 3.0% 4.9% 5.9% 8.9%
 Widow  10.9% 14.0% 6.7% 5.3% 10.2% 9.3% 10.9% 7.6%
Children          
 Yes  19.8% 22.1% 49.1% 48.7% 14.6% 28.1% 42.8% 37.0%
 No  80.2% 77.9% 50.9% 51.3% 75.4% 71.9% 57.2% 63.0%
BCS: breast conserving surgery,  
MAS: mastectomy without breast  
  reconstruction,  
BR: breast reconstruction,  
A-BR: mastectomy with autologous BR, 
I-BR: mastectomy with implant BR,  
GP: general population (Netherlands  
  reference cohort),  
SD: standard deviation 
 
 Values in the same row and sub-table  
not sharing the same superscript (a,b) were 
significantly different at p<0.05 using the 
adjusted Wald test. Cells with no superscript 
were not included in the test. Tests assume 
equal variances. SD values for propensity 
weighted groups are an estimate of the 
population standard deviation.
X  Variables used for propensity weighting. 
*  Mean ages GP-cohort: 46.87 and 58.48 
unadjusted and adjusted by propensity 
score, respectively.
1  Does not add up to 100% due to missing 
answers. 
Table 1. Patient-Reported Characteristics of 1871 Breast Cancer Patients per Surgical Treatment Group,  
before and after Propensity-Weighted Adjustment
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   BCS (95% CI)  MAS (95% CI) A-BR (95% CI) I-BR (95% CI)  GP (95% CI)
Group size (n) 434 386.3 178.6 295.5 N/A
EQ-5D-5L     
Utilities 0.844a  0.805b 0.849a 0.850a 0.833a
  (0.829-0.859) (0.787-0.823) (0.828-0.871) (0.823-0.877) (0.812-0.854)
VAS Score 77.76a 76.48a 79.24a 77.58a 78.88a
  (76.02-79.51) (74.75-78.22) (76.76-81.72) (75.52-79-65) (77.08-80.69)
ReEORTC-QLQ-C30     
Global Health Status 80.00a 79.01a 81.38a 80.16a N/A
  (78.26-81.75) (77.14-80.87) (79.22-83.54) (78.07-82.25) 
Function scales:     
Physical function 84.53a 82.94a 85.62a,b 87.97b N/A
  (83.02-86.04) (81.32-84.55) (83.30-87.85) (85.63-90.31) 
Role function 84.35a 80.70b 84.02a,b 86.02a N/A
  (82.34-86.36) (80.84-87.19) (82.82-89.22) (82.82-89.22) 
Emotional function 85.36a 83.84a 87.00a 85.04a N/A
  (83.36-87.18) (81.90-85.78) (84.47-89.51) (82.40-87.67) 
Cognitive function 84.14a 84.32a 83.67a 84.97a N/A
  (82.21-86.06) (82.32-86.31) (80.53-86.82) (82.29-87.65) 
Social function 88.82a 86.94a 88.02a 87.48a N/A
  (87.01-90.63) (87.01-90.63) (85.54-90.50) (84.40-90.55) 
Symptom scales:     
Fatigue  21.82a 22.54a 22.39a 20.21a N/A
  (19.77-23.87) (20.30-24.77) (19.27-25.51) (17.47-22.94) 
Nausea and vomiting 2.72a 3.31a 2.83a 3.35a N/A
  (1.98-3.46) (2.25-4.38) (1.76-3.90) (1.40-5.30) 
Pain  15.41a 18.93b 17.18a,b 15.89a,b N/A
  (13.56-17.25) (16.53-21.32) (14.07-20.28) 12.87-18.90) 
Dyspnea 14.28a 12.22a 13.39a 10.82a N/A
  (12.18-16.39) (10.12-14.31) (9.75-17.03) (8.06-13.59) 
Insomnia 22.76a 22.69a 20.37a 25.11a N/A
  (20.09-25.44) (19.93-25.44) (16.87-23.87) (21.10-29.11) 
Appetite loss 5.87a 4.08a 3.81a 3.90a N/A
  (4.45-7.30) (2.90-5.26) (2.25-5.37) (1.78-6.03) 
Constipation 6.98a 7.07a 7.96a 5.29a N/A
  (5.38-8.59) (5.34-8.79) (5.29-10.63) (3.80-6.78) 
Diarrhea 4.81a 4.43a 3.24a 4.65a N/A
  (3.52-6.10) (3.14-5.72) (1.96-4.51) (3.11-6.19) 
Financial problems 5.23a 8.22b 12.30b 7.71a,b N/A
  (3.77-6.69) (6.16-10.28) (8.41-16.19) (5.21-10.22) 
EORTC-QLQ-BR23     
Function scales:     
Body image 87.45a 80.49b 82.28b 82.35b N/A
  (85.45-89.45) (78.24-82.74) (79.01-85.55) (79.83-84.88) 
Sexual functioning 27.90a 27.51a 31.95a,b 33.35b N/A
  (25.23-30.58) (24.80-30.22) (28.02-35-89) (29.99-36.72) 
Sexual enjoyment 57.03a 54.82a 64.24b 63.80b N/A
  (53.03-61.02) (51.07-58.57) (59.27-69.21) (60.06-67.54) 
Future perspective 74.51a 71.93a 76.14a 75.03a N/A
  (72.17-76.85) (69.15-74.71) (72.34-79.95) (72.21-77.85) 
Symptom scales:     
Systemic therapy side-effects 12.60a 12.74a 14.41a 13.79a N/A
  (11.57-13.64) (11.49-13.99) (12.41-16.40) (12.08-15.50) 
Breast symptoms 13.45a 9.94b 8.79b 10.82a,b N/A
  (11.80-15.11) (8.60-11.28) (6.88-10.71) (8.36-13.27) 
Arm symptoms 12.68a 17.12b 18.18b 16.82b N/A
  (11.02-14.34) (15.12-19.12) (14.94-21.41) (13.60-20.03) 
Hair loss 4.25a 4.86a 6.50a 5.47a N/A
  (2.78-5.71) (3.37-6.35) (4.02-8.98) (3.58-7.37) 
BREAST-Q     
Satisfaction with Breasts 65.52a 60.65b 71.29c 59.39b N/A
  (63.43-67.61) (58.79-62.51) (68.66-73.92) (57.18-61.60) 
Satisfaction with Outcome N/A N/A 75.75a 66.37b N/A
    (72.52-78.99) (63.66-69.08) 
Psychosocial Well-being 73.77a 66.50b 75.78a,c 71.60a N/A
  (71.70-75.83) (64.68-68.32) (72.94-78.63) (69.30-73.90) 
Sexual Well-being 62.70a 50.00b 63.33a 56.38c N/A
  (59.92-65.48) (47.44-52.55) (58.91-67.75) (52.88-59.88) 
Physical Well-being: Chest 67.39a 73.47b 75.81b,c 72.64b N/A
  (65.17-69.61) (71.78-75.16) (73.56-78.06) (70.61-74.66) 
Physical Well-being: Abdomen N/A N/A 75.81 N/A N/A
    (73.56-78.06)  
Satisfaction Nipple N/A N/A 63.03a 54.96b N/A
    (58.82-67.25) (49.38-60.54) 
BCS: breast conserving surgery, MAS: mastectomy without breast reconstruction, A-BR: mastectomy with autologous breast 
reconstruction, I-BR: mastectomy with implant breast reconstruction, GP: general population. VAS: Visual Analogue Scale, 
95% CI: 95% Confidence interval. Values in the same row and sub table not sharing the same superscript (a,b,c) were 
significantly different at p<0.05 using the adjusted Wald test. Cells with no superscript were not included in the test. Tests 
assume equal variances.
Table 2. Mean patient-reported quality of life scores of 1871 breast cancer patients per  
surgical treatment and the Dutch general population, after propensity-weighted adjustment
       
   BCS (95% CI)  MAS (95% CI) A-BR (95% CI) I-BR (95% CI)  GP (95% CI)
Group size (n) 434 386,3 178,6 295,5 N/A
  
Table 2. Continued Quality of life outcomes
Table 2 presents preference-based HRQoL outcomes at time of survey per group. Unadjusted results for the 
outcomes presented in this table can be found in the appendix table 1. After propensity-weighted adjustment, 
patients treated with MAS reported a statistically significant lower mean EQ-5D score (0.805) compared to 
all other surgical groups (BCS: 0.844; A-BR: 0.849; I-BR: 0.850). Pairwise comparisons of the groups for the 
individual EQ-5D domains reflected these lower means for MAS as well (Figure 1).
Furthermore, for two EORTC-QLQ-C30 functioning scales, statistically significant 
differences were found. First, patients treated with I-BR reported a statistically significant 
higher mean ‘Physical functioning’ (87.97) than patients with BCS (84.53) or MAS (82.94), 
although comparable to A-BR (85.62). Second, I-BR patients reported a statistically 
significant higher mean ‘Role functioning’ (86.02) compared to patients treated with 
MAS (80.70). Within the ‘Symptom Scales’, statistically significant more favorable mean 
scores were found for BCS over MAS for ‘Pain’ (BCS: 15.41, MAS: 18.93;) and ‘Financial 
problems’ (BCS: 5.23, MAS: 8.22).
Based on the EORTC-QLQ-BR23 scores, mean ‘Body image’ was significantly higher 
for BCS-patients (BCS: 87.45; MAS: 80.49; A-BR: 82.28; I-BR: 82.35). BCS-patients 
also reported the lowest mean ‘Arm symptoms’ (BCS: 12.68; MAS: 17.12; A-BR: 18.18; 
I-BR: 16.82). In contrast, ‘Breast symptoms’ on average were more often reported by 
patients treated with BCS (13.45) than MAS (9.94) or A-BR (8.79). Patients with A-BR and 
I-BR reported the highest mean ‘Sexual enjoyment’ (A-BR: 64.24; I-BR: 63.80) compared 
to BCS or MAS (BCS: 57.03; MAS: 54.82).
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Figure 1. Propensity-weighted EQ-5D-5L sub-scale per surgical treatment and weighted 
Dutch general population (GP)
BCS: breast conserving surgery, MAS: mastectomy without breast reconstruction, A-BR: mastectomy 
with autologous breast reconstruction, I-BR: mastectomy with implant breast reconstruction, GP: general 
population. Values in the same domain not sharing the same subscript were significantly different at 
p<0.05 using the adjusted Wald test.
For the Breast-Q scales, patients with A-BR reported the highest mean ‘Satisfaction 
with Breasts’ (A-BR: 71.29) compared to the other groups (BCS: 65.52; MAS: 60.65; 
I-BR: 59.39). Interestingly, ‘Satisfaction with Breasts’ for MAS and I-BR did not differ 
significantly. Mean ‘Satisfaction with Outcome’ and ‘Satisfaction with Nipple’ were 
significantly higher in A-BR than I-BR patients (A-BR: 75.75 vs, I-BR: 66.37; and A-BR: 
63.03; I-BR: 54.96, respectively). MAS-patients reported the lowest mean ‘Psychosocial 
well-being’ (66.50) and ‘Sexual well-being’ (50.00).
Effect of complications on EQ-5D outcomes
A total of 96/615 (16%) of BCS, 112/507 (22%) of MAS, 138/330 (42%) of A-BR, 
and 140/419 (33%) of I-BR-patients reported to have experienced complications 
following surgery (unadjusted groups). After propensity-weighted adjustment, patients 
treated with either BCS, MAS, or A-BR who had experienced complications, showed 
statistically significant lower mean utilities than patients from the same groups who had 
not experienced complications (Table 3). Unadjusted results for the outcomes presented 
in this table can be found in appendix table 2. However, MAS patients without 
complications (0.818) reported means similar to A-BR-patients with complications (0.816) 
and I-BR-patients with complications (0.861). Mean EQ-5D scores of MAS-patients 
who previously had undergone a BR (e.g. failed BR) and who never had undergone a 
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No problems Slight problems Moderate problems Severe problems Unable to/ Extreme problems
   Adjusted group  
 BCS  MAS  A-BR  I-BR   GP 
Group size (n) 434 386.3 178.6 295.5 N/A
No complications 82.3% 75.0% 53.4% 68.4% 100%
Mean EQ-5D-5L 0.859a 0.818b 0.878a 0.847a,b 0.833b
utilities (CI) (0.844-0.875) (0.796-0.840) (0.854-0.902) (0.810-0.884) (0.812-0.854)
Complications 17.7% 25.0% 46.6% 31.6% 
Mean EQ-5D-5L 0.771a 0.771a 0.816a,b 0.861b  N/A
utilities (CI) (0.729-0.812) (0.736-0.806) (0.780-0.853) (0.834-0.888) 
Table 3. Mean EQ-5D-5L utilities for 1871 breast cancer patients with or without surgical 
complications per treatment group and the Dutch general population after propensity-
weighted adjustment
BCS: breast conserving surgery, MAS: mastectomy without breast reconstruction, BR: breast 
reconstruction, A-BR: mastectomy with autologous BR, I-BR: mastectomy with implant BR, GP: general 
population. CI: 95% Confidence interval. Values in the same row and sub table not sharing the same 
superscript (a,b) were significantly different at p<0.05 using the adjusted Wald test. Cells with no 
superscript were not included in the test. Tests assume equal variances.
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For both BR groups, problems reported per EQ-5D domain were stratified by complications 
(Figure 2). A-BR patients with complications reported statistically significant more often 
problems for the ‘Usual activities’ and “Pain/Discomfort” domain than A-BR patients without 
complications.
Figure 3 includes boxplots presenting timelines of the utilities for A-BR and I-BR patients 
who had experienced complications, unadjusted by propensity weighting. In the first three 
years after a complicated BR, a relatively large proportion of A-BR patients experienced 
a severe impact on HRQoL. This negative impact on HRQoL recovered with time for both 
treatment modalities. However, a larger proportion of I-BR patients seemed to recover up 
to the degree that they did not report problems on any of the EQ-5D dimensions within 
6-9 years after the last BR surgery, compared to a much smaller portion of A-BR patients.
Discussion
This study aimed to compare HRQoL outcomes for four common surgical breast cancer 
treatment options (BSC, MAS, A-BR, I-BR) to improve the evidence and consequently 
decision-making about breast cancer surgery. We found that MAS-patients reported 
A-BR: mastectomy with autologous BR, I-BR: mastectomy with implant BR
Figure 3. EQ-5D-5L utilities over time in years (time between last BR and questionnaire) for 
breast cancer patients following breast reconstruction with complications
the lowest mean HRQoL (EQ-5D) and functioning (EORTC-QLQ-C30). Based on the 
Breast-Q, A-BR-patients had statistically significant higher ‘satisfaction with outcome’ 
and ‘satisfaction with breasts’ and ‘sexual well-being‘ scores than I-BR patients. Patients 
with complications (except for I-BR) reported statistically significant lower HRQoL (EQ-5D) 
than patients without complications; complications in A-BR patients resulted in a 
substantially lower HRQoL than in I-BR patients.
The results show the added value of breast conservation and reconstruction compared 
to MAS, however, the differences between BCS, I-BR, and A-BR were subtle. Indeed, 
we found many statistically significant differences, but given the high statistical power of 
our large study most of them were small. So, on average we found few clinically relevant 
differences between BCS, I-BR, and A-BR for the various HRQoL domains. However, the 
benefits of these subtle differences over a long time are a good reason to consider them in 
clinical decision-making, specifically when considering the effects of complications and 
the patients’ attitude towards the risks of complications.
Only one other study that reported EQ-5D derived utilities for surgically-treated breast 
cancer patients receiving BR was found (Immediate IBR-patients, mean score: 0.83).14 
We found lower mean HRQoL scores reported by MAS-patients and benefits in 
Figure 2. EQ-5D-5L sub-scale contrasting A-BR and I-BR with or without surgical  
complication (unadjusted for propensity score) 
A-BR: mastectomy with autologous BR, I-BR: mastectomy with implant BR, GP: general population. 
C = surgical complications; NC = no surgical complications. Values in the same domain not sharing 
the same subscript were significantly different at p<0.05 using the Adjusted Wald test. Cells without 
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some HRQoL domains for BCS-patients (higher ‘Body Image’ and more favorable 
‘Arm Symptom’) over all other surgically treated groups, which confirms previously 
reported results.15,32,20 The benefits of A-BR compared to I-BR (higher mean ‘Satisfaction 
with Breasts/Outcome/Nipple’, and ‘Sexual Well-being’) were also reported by Santosa 
et al.22 However, in contrast, both the present study and Thorarinsson et al.33 did not 
find statistically significant differences between A-BR and I-BR on either EQ-5D-5L or 
EORTC-QLQ outcomes. So, although the BREAST-Q results suggest that the patients’ 
perception of their reconstructed breast(s) is favorable for A-BR over I-BR, this does not 
necessarily lead to better outcomes in terms of overall HRQoL.
The second aim was to assess the impact of complications after different surgical 
treatments. Indeed, if any clinically relevant differences were found,34 they seemed to be 
related to complications. Specifically for A-BR, one should not ignore the impact of 
complications.35 A-BR patients with complications (versus those without complications) 
had statistically significant lower mean utilities as measured with the EQ-5D, and more 
often had problems in the ‘Usual activities’ and ‘Pain/Discomfort’ domains. Also, mean 
scores recovered faster for I-BR patients than A-BR patients. Finally, a larger proportion 
of A-BR patients never recovered up to the degree that they did not report problems on 
any of the EQ-5D dimensions.
The faster recovery after complications of I-BR patients could explain why the utilities in 
patients with and without complications did not differ statistically. The symptoms and the 
longer lasting impact of complications in A-BR patients may be inherent to the type of 
complications associated with these procedures. More specifically, failure of an I-BR is often 
due to an infection, resulting in removal of the implant, later often followed by a new I-BR. 
Total flap failure following A-BR requires a new and additional donor-site, with its own donor-
site issues and complication risks. Women experience BR (flap) failure as an emotionally 
very difficult life event,36 although previous studies have shown that physical and mental 
health after a BR complication generally recover to normal levels after a period of time.37,38
By measuring HRQoL using multiple, validated PROMs in a large sample of patients 
following different types of breast cancer surgery, we were able to improve earlier, 
smaller and less consistent attempts to assess HRQoL in surgically-treated breast 
cancer patients. Our statistically significant results confirm the findings of studies 
mentioned previously,15,20,22,32,35 thereby supporting the added value of breast conservation 
and reconstruction for breast cancer patients.
Furthermore, no predominant treatment option was found. This stresses the idea that 
all treatment options (which are physically feasible) should be considered for every 
patient. The ultimate treatment decision should be predominantly based on the patient’s 
preferences, resulting in the alignment of the favorable assets (or domain scores) of each 
procedure and the patient’s goals and expectations with the expected final result of 
each procedure as well as their attitudes towards complication risks. Although we have 
investigated decision-making in a previous study in a similar cohort of patients39, it would 
have been interesting to have insight in the treatment rationale for the current patient 
cohort.
This study demonstrates the utilization of the unique assets of the EQ-5D, a ‘preference-
based’, standardized generic measure of health status which is suitable for a wide 
comparison of treatment options.40,41 A benefit of this preference-based HRQoL measure 
compared to commonly applied ‘non-preference-based’ measures like the EORTC and 
Breast-Q is that its outcomes can be aggregated over time and, after multiplication with 
survival time, provides Quality Adjusted Life Years (QALYs).41 The EQ-5D utilities can be 
related to the time period of each health state, and can therefore combine the ‘utility’ of 
the advantages and disadvantages, such as complications of surgical procedures. Note 
that our data were not able to fully solve the question how the utility of the benefits of a 
surgical procedure relates to the disutility of complications, as this requires longitudinal 
data to represent the EQ-5D values and the time lived with or without a given complication. 
Nevertheless, the present data can still provide insights in the trade-off between benefits 
and complications of the different surgical procedures.
Of further importance is that previous studies have not yet described ‘utilities’ for the 
complete range of breast cancer surgery options. This currently complicates the 
implementation of health economics and reimbursement decision-making. Clinical 
treatment value should be related to healthcare costs, which is the ultimate goal towards 
creating value-based health care.42 In our subsequent study, we will relate costs to the 
outcomes we found in the present study.
Some limitations are relevant in the interpretation of our results. First, although 
propensity-weighted adjustment was employed to minimize the effects of bias caused 
by including patients from an observational cohort, one cannot exclude that relevant 
variables may still have influenced the results of our study.43 For instance, surgical 
treatment selection might be based on severity of comorbidities or performance status, 
which were both not available in our data. Non-response bias could have been induced 
by socioeconomic and procedure-related differences, as described by Berlin et al.44 
Besides, surveys introduce a certain arbitrariness, as patients might understand or 
interpret questions or experiences other than intended.
We conclude that HRQoL of MAS-patients was often the lowest, supporting the added 
value of breast conservation and reconstruction in breast cancer patients. Furthermore, 
we found that each surgical procedure has subtle favorable assets, the most notable 
related to complications: a complication in A-BR patients resulted in a substantially lower 
HRQoL than in I-BR patients and MAS-patients without complications had similar or lower 
mean EQ-5D scores to A-BR or I-BR patients with complications. This could support a 
discussion about the alignment of the patient’s goals, expectations and attitudes towards 
complication risks with the expected final result of each procedure.
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    Unweighted groups     Propensity weighted groups   
   BCS (95% CI)  MAS (95% CI)  A-BR (95% CI)  I-BR (95% CI)  GP (95% CI)  BCS (95% CI)  MAS (95% CI) A-BR (95% CI) I-BR (95% CI)  GP (95% CI)
Group size (n) 615 507 330 419 505 434 386.3 178.6 295.5 N/A
EQ-5D-5L     
Utilities 0.854a  0.784b  0.837a  0.856a  0.856a  0.844a  0.805b 0.849a 0.850a 0.833a
  (0.840-0.868) (0.769-0.800) (0.818-0.856) (0.839-0.873) (0.841-0.872) (0.829-0.859) (0.787-0.823) (0.828-0.871) (0.823-0.877) (0.812-0.854)
VAS Score 78.60a  74.59b  78.47a  78.34a  80.27a  77.76a 76.48a 79.24a 77.58a 78.88a
  (77.22-79.22) (73.09-76.10) (76.59-80.34) (76.69-80.01) (78.75-81.78) (76.02-79.51) (74.75-78.22) (76.76-81.72) (75.52-79-65) (77.08-80.69)
EORTC-QLQ-C30           
Global Health Status 80.89a 77.98b 80.86a,b 80.42a,b N/A 80.00a 79.01a 81.38a 80.16a N/A
  (79.52-82.27) (76.3-79.66) (78.94-82.78) (78.75-82.08)  (78.26-81.75) (77.14-80.87) (79.22-83.54) (78.07-82.25) 
Function scales:           
Physical function 85.07a  79.86c  86.66a,b  89.15b  N/A 84.53a 82.94a 85.62a,b 87.97b N/A
  (83.75-86.4) (78.14-81.57) (84.86-88.46) (87.82-90.49)  (83.02-86.04) (81.32-84.55) (83.30-87.85) (85.63-90.31) 
Role function 85.29a  77.96b  84.09a  86.04a  N/A 84.35a 80.70b 84.02a,b 86.02a N/A
  (83.5-87.07) (75.7-80.23) (81.57-86.61) (83.95-88.14)  (82.34-86.36) (80.84-87.19) (82.82-89.22) (82.82-89.22) 
Emotional function 85.51a  83.33a  85.63a  84.65a  N/A 85.36a 83.84a 87.00a 85.04a N/A
  (84.01-87.02) (81.59-85.08) (83.49-87.77) (82.63-86.66)  (83.36-87.18) (81.90-85.78) (84.47-89.51) (82.40-87.67) 
Cognitive function 85.72a  84.26a  82.02a  83.89a  N/A 84.14a 84.32a 83.67a 84.97a N/A
  (84.14-87.3) (82.43-86.08) (79.73-84.31) (81.73-86.05)  (82.21-86.06) (82.32-86.31) (80.53-86.82) (82.29-87.65) 
Social function 89.86a  86.00b  86.16a,b  86.69a,b N/A 88.82a 86.94a 88.02a 87.48a N/A
  (88.38-91.35) (84.08-87.92) (83.91-88.41) (84.62-88.76)  (87.01-90.63) (87.01-90.63) (85.54-90.50) (84.40-90.55) 
Symptom scales:           
Fatigue  21.17a  24.59a 23.47a  20.81a  N/A 21.82a 22.54a 22.39a 20.21a N/A
  (19.38-22.97) (22.46-26.73) (21.06-25.87) (18.61-23.01)  (19.77-23.87) (20.30-24.77) (19.27-25.51) (17.47-22.94) 
Nausea and vomiting 2.98a  3.62a  2.88a  3.39a  N/A 2.72a 3.31a 2.83a 3.35a N/A
  (2.27-3.69) (2.65-4.6) (1.9-3.86) (2.3-4.48)  (1.98-3.46) (2.25-4.38) (1.76-3.90) (1.40-5.30) 
Pain  14.99a  20.16b  16.72a,b 15.95a  N/A 15.41a 18.93b 17.18a,b 15.89a,b N/A
  (13.3-16.68) (18.02-22.3) (14.35-19.08) (13.73-18.17)  (13.56-17.25) (16.53-21.32) (14.07-20.28) 12.87-18.90) 
Dyspnea 13.44a  14.56a  12.46a,b 9.65b  N/A 14.28a 12.22a 13.39a 10.82a N/A
  (11.67-15.22) (12.44-16.68) (10.13-14.8) (7.81-11.49)  (12.18-16.39) (10.12-14.31) (9.75-17.03) (8.06-13.59) 
Insomnia 22.93a  24.44a  23.23a  25.04a  N/A 22.76a 22.69a 20.37a 25.11a N/A
  (20.68-25.17) (21.88-27) (20.09-26.38) (22.21-27.87)  (20.09-25.44) (19.93-25.44) (16.87-23.87) (21.10-29.11) 
Appetite loss 6.02a  5.34a 3.94a  3.75a  N/A 5.87a 4.08a 3.81a 3.90a N/A
  (4.7-7.33) (3.88-6.79) (2.56-5.32) (2.36-5.13)  (4.45-7.30) (2.90-5.26) (2.25-5.37) (1.78-6.03) 
Constipation 6.78a  7.85a  8.59a  6.38a  N/A 6.98a 7.07a 7.96a 5.29a N/A
  (5.45-8.1) (6.23-9.48) (6.31-10.86) (4.73-8.03)  (5.38-8.59) (5.34-8.79) (5.29-10.63) (3.80-6.78) 
Diarrhea 4.82a  4.82a  4.14a  4.70a  N/A 4.81a 4.43a 3.24a 4.65a N/A
  (3.65-6) (3.57-6.07) (2.6-5.68) (3.24-6.17)  (3.52-6.10) (3.14-5.72) (1.96-4.51) (3.11-6.19) 
Financial problems 5.04a  7.51a,c  11.92b  8.79b,c  N/A 5.23a 8.22b 12.30b 7.71a,b N/A
  (3.86-6.22) (5.88-9.14) (9.27-14.57) (6.7-10.89)  (3.77-6.69) (6.16-10.28) (8.41-16.19) (5.21-10.22) 
           (continued)
Table 1. Mean patient-reported quality of life scores of 1871 breast cancer patients per surgical treatment 




    Unweighted groups     Propensity weighted groups   
   BCS (95% CI)  MAS (95% CI)  A-BR (95% CI)  I-BR (95% CI)  GP (95% CI)  BCS (95% CI)  MAS (95% CI) A-BR (95% CI) I-BR (95% CI)  GP (95% CI)
Group size (n) 615 507 330 419 505 434 386.3 178.6 295.5 N/A
EORTC-QLQ-BR23      
Function scales:           
Body image 89.19a  79.43b  80.65b  80.10b  N/A 87.45a 80.49b 82.28b 82.35b N/A
  (87.72-90.67) (76.51-82.35) (78.3-83) (78.07-82.14)  (85.45-89.45) (78.24-82.74) (79.01-85.55) (79.83-84.88) 
Sexual functioning 28.48a,c  31.14a,b 35.71b  25.13c  N/A 27.90a 27.51a 31.95a,b 33.35b N/A
  (26.34-30.61) (28.3-33.97) (32.91-38.5) (22.71-27.54)  (25.23-30.58) (24.80-30.22) (28.02-35-89) (29.99-36.72) 
Sexual enjoyment 55.73a,c  61.93a,b  65.04b  53.80c  N/A 57.03a 54.82a 64.24b 63.80b N/A
  (52.42-59.03) (57.5-66.36) (61.71-68.37) (50.19-57.42)  (53.03-61.02) (51.07-58.57) (59.27-69.21) (60.06-67.54) 
Future perspective 75.57a  71.97a,b  73.18a,b 71.38b  N/A 74.51a 71.93a 76.14a 75.03a N/A
  (73.61-77.54) (68.97-74.97) (70.67-75.69) (68.92-73.84)  (72.17-76.85) (69.15-74.71) (72.34-79.95) (72.21-77.85) 
Symptom scales:           
Systemic therapy side-effects 12.35a  15.20b  14.02a,b  13.22a,b  N/A 12.60a 12.74a 14.41a 13.79a N/A
  (11.35-13.35) (13.64-16.75) (12.66-15.38) (12.06-14.38)  (11.57-13.64) (11.49-13.99) (12.41-16.40) (12.08-15.50) 
Breast symptoms 12.71a  8.77b  9.68b  10.69a,b  N/A 13.45a 9.94b 8.79b 10.82a,b N/A
  (11.41-14.02) (7.4-10.13) (8.18-11.18) (9.33-12.05)  (11.80-15.11) (8.60-11.28) (6.88-10.71) (8.36-13.27) 
Arm symptoms 11.31a  18.56b  15.38b  17.57b  N/A 12.68a 17.12b 18.18b 16.82b N/A
  (9.91-12.71) (16.29-20.84) (13.41-17.36) (15.77-19.38)  (11.02-14.34) (15.12-19.12) (14.94-21.41) (13.60-20.03) 
Hair loss 3.93a  7.26b  5.95a,b  5.59a,b  N/A 4.25a 4.86a 6.50a 5.47a N/A
  (2.77-5.1) (5.05-9.47) (4.06-7.83) (3.98-7.2)  (2.78-5.71) (3.37-6.35) (4.02-8.98) (3.58-7.37) 
BREAST-Q           
Satisfaction with Breasts 67.84a  60.22b  70.74a  59.53b  N/A 65.52a 60.65b 71.29c 59.39b N/A
  (66.15-69.52) (58.64-61.81) (68.67-72.81) (57.9-61.17)  (63.43-67.61) (58.79-62.51) (68.66-73.92) (57.18-61.60) 
Satisfaction with Outcome N/A N/A 75.39a  66.35b  N/A N/A N/A 75.75a 66.37b N/A
    (72.81-77.96) (64.18-68.53)    (72.52-78.99) (63.66-69.08) 
Psychosocial Well-being 75.31a  66.15c  74.09a,b  71.11b  N/A 73.77a 66.50b 75.78a,c 71.60a N/A
  (73.61-77.01) (64.58-67.71) (71.97-76.21) (69.19-73.03)  (71.70-75.83) (64.68-68.32) (72.94-78.63) (69.30-73.90) 
Sexual Well-being 64.39a 48.31d  61.58b  56.82c  N/A 62.70a 50.00b 63.33a 56.38c N/A
  (62.20-66.57) (45.96-50.66) (58.79-64.38) (54.59-59.06)  (59.92-65.48) (47.44-52.55) (58.91-67.75) (52.88-59.88) 
Physical Well-being: Chest 68.90a  73.41b  74.95a  72.75b N/A 67.39a 73.47b 75.81b,c 72.64b N/A
  (67.45-70.36) (71.84-74.97) (73.15-76.74) (71.06-74.45)  (65.17-69.61) (71.78-75.16) (73.56-78.06) (70.61-74.66) 
Physical Well-being: Abdomen N/A N/A 78.25 N/A N/A N/A N/A 75.81 N/A N/A
    (75.95-80.56)     (73.56-78.06)  
Satisfaction Nipple N/A N/A 63.63a  55.28b  N/A N/A N/A 63.03a 54.96b N/A
    (60.03-67.23) (50.66-59.89)    (58.82-67.25) (49.38-60.54) 
BCS: breast conserving surgery, 
MAS:  mastectomy without breast reconstruction, 
A-BR:  mastectomy with autologous breast reconstruction, 
I-BR:  mastectomy with implant breast reconstruction, 
GP:  general population. 
VAS:  Visual Analogue Scale, 
95% CI:  95% Confidence interval.
Values in the same row and subtable not sharing the same 
superscript (a,b) were significantly different at p<0.05 using 
the adjusted Wald test. Cells with no superscript were not 




    Unadjusted group     Adjusted group   
   BCS  MAS  A-BR  I-BR  GP  BCS  MAS  A-BR  I-BR   GP 
Group size (n) 615 507 330 419 505 434 386.3 178.6 295.5 N/A
No complications 84.5% 77.9% 58.2% 66.6% 100% 82.3% 75.0% 53.4% 68.4% 100%
Mean EQ-5D-5L utilities (CI) 0.869a 0.800b 0.872a 0.868a 0.856a 0.859a 0.818b 0.878a 0.847a,b 0.833b
  (0.854-0.883) (0.781-0.818) (0.848-0.89) (0.848-0.887) (0.842-0.871) (0.844-0.875) (0.796-0.840) (0.854-0.902) (0.810-0.884) (0.812-0.854)
            
Complications 15.6% 22.1% 41.8% 33.4% N/A 17.7% 25.0% 46.6% 31.6% 
Mean EQ-5D-5L utilities (CI) 0.770a 0.753a 0.791a 0.839b N/A 0.771a 0.771a 0.816a,b 0.861b  N/A
  (0.731-0.809) (0.717-0.789) (0.759-0.823) (0.807-0.872)  (0.729-0.812) (0.736-0.806) (0.780-0.853) (0.834-0.888) 
BCS: breast conserving surgery, 
MAS: mastectomy without breast reconstruction, 
BR: breast reconstruction, 
A-BR: mastectomy with autologous BR, 
I-BR: mastectomy with implant BR, 
GP: general population. 
CI: 95% Confidence interval. 
Values in the same row and subtable not sharing the same 
superscript (a,b) were significantly different at p<0.05 using 
the adjusted Wald test. Cells with no superscript were not 
included in the test. Tests assume equal variances.
Table 2. Mean EQ-5D-5L utilities for 1871 breast cancer patients with or without surgical complications per 
treatment group and the Dutch general population, before (left) and after (right) propensity-weighted adjustment
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The goal of postmastectomy breast reconstruction (BR) is to improve the 
quality of life of patients. However, complications following autologous (A-BR) 
and implant-based breast reconstruction (I-BR) occur frequently and may 
even lead to BR-failure, which can be a distressing event for both patients and 
surgeons. The current study therefore looks at the experiences of both patients 
and surgeons after a BR-failure.
Methods 
Patients with a failed BR from a large multicenter cohort study and participating 
plastic surgeons were invited to participate in semi-structured interviews focusing 
on their experiences. The interviews were analyzed according to the principles 
of grounded theory. 
Results 
Fourteen patients with a failed I-BR, four patients with a failed A-BR and four 
plastic surgeons participated. Three main categories emerged from the data: 
personal experiences with BR-failure, the motives for a redo of a failed BR, and 
patient-surgeon communication. Patients would like to be treated with more 
attention to their personal feelings and lives, instead of being approached from 
a purely medical-technical perspective. Surgeons may experience feelings of 
guilt leading to the strong urge to fix the failed BR, whereas patients may be 
less inclined to undergo additional operations. Patients want to know what the 
choice for a particular type of BR would mean to their personal lives. The impact 
of I-BR-failure may be underestimated and requires the same degree of 
intensive aftercare and attention. 
Conclusions 
Implementing the recommendations of this study in clinical practice may 







A significant proportion of breast cancer patients either require or actively opt for a 
mastectomy. Breast reconstruction (BR) aims to reduce the negative effects the loss of 
one or both breasts may have on psychosocial health, body image, and sexual function.1 
However, BR also has relatively high risks of complications, and can sometimes even 
result in the complete loss of the reconstructed breast (BR-failure). A recent large-scale 
prospective study reported BR-failure rates of 7.1% for implant-BR (I-BR) and 1.3-2.1% 
for autologous-BR (A-BR).2
Few studies have investigated the potential negative psychological consequences 
of a BR-failure. One recent qualitative study showed that an A-BR failure has a large 
emotional impact on patients.3 Quantitative studies by our research group have shown 
that postoperative complications (including BR-failures) were associated with substantial 
psychological distress in the short-term, but that in the long-term, these levels of distress 
returned to values comparable to that of patients without such postoperative 
complications.4,5 However, quantitative studies do not provide insight into which 
experiences lead to distress in patients confronted with a BR-failure. Qualitative studies 
which investigate the effect of an implant-based BR-failure on patients’ quality of life are 
lacking.
In addition, plastic surgeons who perform the procedure may also be profoundly affected 
by the event of a BR-failure. Several studies have shown that the occurrence of serious 
adverse events may have a strong impact upon the healthcare provider involved, also 
referred to as the “second victim” phenomenon.6,7
The aim of this study was to explore both patient and surgeon views and experiences 
of A-BR or I-BR failure, in order to obtain insights that could facilitate improvement in 
care for both parties.
Methods
Study Design
We performed face-to-face, semi-structured, in-depth interviews with patients following 
a failed BR and with plastic surgeons involved in BR-surgery (J.G. and M.H.). Interview 
data was analyzed according to the principles of grounded theory. This method was 
chosen because of its ability to develop an explanatory theory that is grounded in and 
systematically derived from data with minimal interference of preconceived ideas of 
the researchers or existing theories8-10. It involves a cyclical process of collecting data, 
analyzing it, developing a provisional coding scheme, using it to suggest further sampling 




Eighteen patients (out of 39 BR failure patients) were included, of which four patients 
had undergone A-BR and 14 I-BR. Thirteen patients declined to participate, one was not 
approached as she was undergoing treatment for metastatic breast cancer, one was not 
approached because of complex psychopathology, and six were not approached because 
of saturation of the specific study group. Four plastic surgeons were included. At the time 
of interview, patients were on average 52 years old (SD 11.5) and their age varied between 
30 and 66 years. Two male and two female plastic surgeons participated of whom three 
had extensive experience with both I-BR and A-BR. One surgeon was mainly experienced 
in performing I-BR. Their experience as a certified plastic surgeon ranged between 
8 and 15 years. One third of the patients had undergone a prophylactic mastectomy. The 
interviews with both patients and surgeons lasted about one hour on average. Three main 
categories emerged from analysis of the data: 1. personal experiences with BR-failure; 
2. motives for a redo of the failed BR; and 3. patient-surgeon communication.
1. Personal experiences with BR-failure
1.1 Experiences of the patient
1.1.1. The patients’ personal experience of their BR-failure
The patients’ experience of their BR-failure could be divided in two subthemes: physical 
impact and psychosocial impact. Patients experienced several, sometimes persisting, 
physical symptoms after BR-failure, including pain, weight loss and fatigue. Cognitive 
problems were also described, such as memory loss and concentration problems, which 
they ascribed to repeated general anesthesia in a short period.
Besides the physical impact, BR-failure also had a high psychosocial impact. In our 
sample, BR-failure often led to body dissatisfaction. Women stated that their bodies 
looked horrible after the failure and one participant even described the feeling of being 
mutilated (“I hated my body so much. It was a battlefield. Yes, it is… it is just disgusting. 
Just sickening. That is what it looked like.” – 2045). Almost each participant described 
that they felt less feminine, which negatively affected their self-esteem. They described 
that they felt ashamed of their bodies after the BR-failure. One woman, who had been 
able to overcome her shame after an extended period of time, perceived this as a great 
victory (“I let a few tears of joy when I was wearing my bikini again. I thought: I have come 
this far… this is the reason why I have done this. And then I thought: this is a big victory 
for myself.” – 4079).
Patients had experienced a broad variety of emotions during the failed BR course, 
including feelings of fear, anger, disappointment and relief. Most patients preferred to 
use their own social system to support them in coping with these feelings over seeking 
analysis of the data by two independent researchers (C.K. and L.H.). BR-failure was taken 
as one group and in principle no distinction was made between A-BR and I-BR. This 




Patients with a failed BR who had participated in a prospective multicenter follow-up 
study on postmastectomy BR for breast cancer or prophylaxis were invited to participate 
in this study to obtain a representative sample.4,5,9,10 Due to the limited number of patients 
with an A-BR failure in the study, additional patients from one of the participating 
hospitals were recruited. All patients signed an informed consent.
Surgeons
Plastic surgeons involved in BR were invited to participate in this study. The plastic 
surgeons provided oral informed consent.
Data Collection
A topic-based interview guide was used to conduct the interviews in a semi-structured 
manner. For patients it focused on: medical history, communication with their plastic 
surgeon during the BR trajectory, the motivation for a potential redo of the failed BR 
and impact of the failed BR. For plastic surgeons: first reactions to a failed BR, ideas on 
consequences of a failed BR for the patient, ideas on aftercare for patients and (emotional) 
impact of the BR-failure on him/herself. Participants were encouraged to elaborate on the 
different topics. Additional questions were asked to acquire specific details beneficial to 
the study. All interviews were audio-recorded and transcribed verbatim.
Data Analysis
Data was imported and analyzed using NVivo software.11 Next, two members of the 
research team (C.K and L.H.) independently performed open coding in which the 
researchers independently went through the transcripts line by line and assigned 
labels to text elements, which were then grouped into key concepts. This process 
was continued until the two researchers separately worked through the entire set of 
interviews where the coding framework continually developed and was adjusted based 
on the data. After this phase the two researchers together compared and integrated 
their coding frameworks and clustered the derived concepts into themes. Subsequently, 
the research team (C.K., L.H., L.K. and S.I.) met to discuss initial findings followed by 
comprehensive review and adjustment. Themes were grouped into categories and a final 
theoretical framework was agreed upon. The accompanying codebook was used for the 
complete dataset. The results of this final analysis are presented in the results section.
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2. Motives for a redo of a failed breast  
reconstruction
2.1 Patients’ motives to undergo or not undergo  
a second BR
2.1.1. Motives in favor of a second BR
The most common reason for undergoing a second BR was body dissatisfaction. One 
woman stated that the daily confrontation with her deformed body made her feel so 
miserable, that she had no other choice than to undergo another reconstruction. Another 
woman reported she had been persuaded by her surgical oncologist (“I was done with it; 
I had closed this topic… The next year, he mentioned it again. He said: ‘You have to do 
something about it, it can be much better.’” - 2069). Other reasons mentioned include 
young age, confidence in a positive outcome and frustration related to using an external 
prosthesis.
2.1.2 Motives against a second BR
The most mentioned motives for not undergoing a second BR were the risks and fear of 
complications, fear of putting health at risk, and the burden of the surgery and its recovery 
(“…but I don’t want it anymore. I’ve been poked and picked at enough, it’s done, I leave 
it like this... I’m tired of surgery and pain.” - 4083). The impact of undergoing general 
anesthesia was mentioned frequently as a part of the surgery’s burden. Other reasons 
included the feeling that it was unnecessary at their older age, acceptance of the current 
situation, and uncertainty regarding the outcome.
2.2 The plastic surgeons’ view regarding a second  
BR attempt
Compared to the patients, responses from the surgeons were less balanced. One plastic 
surgeon stated that in his/her practice every woman with a failed autologous reconstruction 
undergoes a second BR, and two reported that the vast majority of their patients choose 
another reconstruction. The plastic surgeons agreed that patients need time to recover 
mentally as well as physically from the BR-failure before undergoing the next surgery 
(“Sometimes I suggest you first have to feel comfortable again before you can take the 
next step.” - PCH 3). 
professional help, even if it had been offered to them. Some women described negative 
consequences for their sexual relationship. They described issues with intimacy due to 
shame and less spontaneity in initiating sexual activities (“You are ashamed to death when 
you’re naked in the bathroom or in bed. Lights off, bye, I’ll hide myself. I always wear a 
shirt now, while I used to wear nothing when sleeping. Yes, you just feel very ugly” – 2045). 
Some women mentioned they find it a difficult topic to discuss with their partner. A few 
even feared that their relationship would collapse (“I am worried, because if a man misses 
passion… what if he meets someone else who can fulfill those needs? Yes… I do not want 
to think about that.” – 2089).
1.1.2 The patients’ perceptions of their plastic surgeon’s experience of the BR-failure
Some patients thought that their plastic surgeon felt sorry for them, because he or she 
was very committed to the patient during the entire course (“He was literally crying while 
he was cycling from one hospital to another, because he wants to be there, because 
he wants to help you. He had been rinsing those implants for like half an hour. That is 
incredible.” – 2006). Other patients thought that their plastic surgeon did not necessarily 
feel bad for them, rather he/she found it especially difficult for himself/herself. Those 
women were able to empathize with their surgeon’s frustrations and possible feelings of 
guilt and failure.
1.2 Experiences of the plastic surgeon
1.2.1 The plastic surgeons’ experience of the BR-failure
Factors of influence on how surgeons experienced a BR-failure included “the chemistry” 
with the patient, type of reconstruction (A-BR vs I-BR) and the cause of the BR-failure. 
Regarding the type of reconstruction, the surgeons described a greater impact if it had 
been an A-BR-failure (“The loss of a tissue expander or breast implant, that is of course 
annoying. Everyone is frustrated with such a loss. But I am really upset with the loss 
of a DIEP flap. I really do not like that” – PCH1). The plastic surgeons questioned the 
possible causes of the failure. One surgeon stated it would be easier to accept a failure if 
his performance would not be the cause of it, whereas another plastic surgeon indicated 
their preference to make a clear mistake, instead of not knowing the cause at all. Although 
a BR-failure does not occur often, the plastic surgeons reported that it has had a big 
impact on their self-confidence. One plastic surgeon even considered to stop performing 
breast reconstructions. Plastic surgeons also reported they had become very cautious in 
their patient selection, implementing more (unnecessary) backups in the procedure. They 
stated it had taken them a few successful A-BRs before they had been able to return to 
normal practice again. They report that they now more clearly point out the possibility of a 
BR-failure while informing the patient.
1.2.2 The plastic surgeons’ perceptions of the patient’s experience of the BR-failure
All plastic surgeons acknowledged that a BR-failure has negative consequences for 
patients’ emotional wellbeing, body-image, relationship and sexuality, however they did 
not elaborate much further on it.
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3.2.2 Communication with the patient after a BR-failure
Some surgeons emphasized the importance of clear and honest communication about 
the cause of the failure and follow-up steps. They pointed out the importance of their own 
involvement in the situation and social support for the patient was widely acknowledged 
by the plastic surgeons. However, the usefulness of professional psychological support 
was questioned by the plastic surgeons. (“I think it is very important for the surgeon to 
keep in direct contact with the patient and not someone else ... I think that doesn’t help, 
not very much though. Maybe if the patient gets a psychological reaction, such as a reac-
tive depression or something. But I have never seen that before. But I do know that the 
patient is very much in need of contact with the surgeon.” - PCH 2).
Discussion
A finding that may have important clinical implications and that would be easy to 
implement relates to the strong focus of plastic surgeons on A-BR failure. Although 
the surgeons were interviewed about the impact of BR-failure regardless of type of 
reconstruction, they almost exclusively talked about the impact A-BR had had on 
them with limited discussion about the impacts of I-BR. One surgeon even explicitly 
acknowledged they are only intensively involved in the aftercare when there is an A-BR 
failure. This suggests that the impacts of I-BR are underestimated. This is in contrast to 
how a patient experiences the failure, because nothing in our study has suggested that 
I-BR patients experienced their BR-failure as less distressing than A-BR patients. One 
might even suggest some I-BR patients were more taken aback by their failed BR, as they 
seemed less prepared and informed about this possible complication than A-BR patients. 
Although an I-BR-failure may have a less severe impact on the plastic surgeon, this is not 
necessarily the case for the patient. Therefore, the same high degree of involvement in 
the aftercare for the patient and attention for the psychosocial impact is required for I-BR 
patients, specifically when taking the considerably higher rate of I-BR failures into account.
One of the most frequently returning themes among patients was their desire to be seen and 
treated as an individual human being, with attention being given to their personal feelings 
and life, instead of being approached from a purely medical-technical perspective, in line 
with earlier research.3 More concretely, patients expressed the desire their plastic surgeon 
would ask them how they were doing and explicitly acknowledged the emotional impact 
of the BR-failure.
Even a simple question that confirms the surgeon’s empathy like “How are you doing?” 
or the acknowledgement “It’s really tough, isn’t it?” would make a difference for the 
patients. So, why do doctors not address the psychosocial aspects/impact of the 
BR-failure? A possible explanation lies in the fact that the occurrence of a serious adverse 
event (i.e., a complication) may also have quite an emotional impact on the surgeon 
involved.6,7,12 This impact seems greatest in the period directly after the incident, and this 
3. Patient-surgeon communication
3.1 Patients’ experiences with communication with  
the surgeon
3.1.1. Contact with the surgeon
Both positive and negative experiences in relation to contact with the surgeon were 
reported. Some women noted that a good relationship with their plastic surgeon 
increased their confidence in a positive outcome. Other women decided to go to another 
plastic surgeon as a result of the contact they had with their plastic surgeon. Arrogance 
was mentioned a number of times as an irritating quality (“If they were only just a little 
bit human and not that proud-hearted... Those plastic surgeons are that terribly arrogant, 
you cannot really say to them that something went wrong.” – 2045).
3.1.2 Patients’ experience with receiving information
Patients stressed the need to receive adequate information about: the various treatment 
options; the psychosocial impact of a BR in general and the possible outcomes when 
things do not go according to plan, for instance in case of failure. The need for adequate 
preoperative information regarding the psychosocial impact was mentioned most often. 
Patients missed information about, for example, body-image, the possible impact on their 
relationships and intimacy, and the postoperative care. Furthermore, women wished to 
have received a clearer picture of what the different outcomes would have meant for them 
in their daily lives.
3.1.3 Communication about the BR-failure
An overarching theme that emerged from the discussions on communication about 
the BR-failure was the desire by patients to be seen and treated as individual human 
beings, with regard being given to their personal feelings and lives. All women underscored 
the importance of empathy and they expressed a desire for explicit recognition of the 
emotional impact of the BR-failure by their plastic surgeon. The patients considered it 
important that the plastic surgeon be accessible, honest and dedicated and that they 
create time to discuss their personal needs and issues in a compassionate manner.
3.2 Plastic surgeons’ views on communicating with the 
patient
3.2.1 Information provision and counselling
All plastic surgeons acknowledged the importance of providing adequate information. They 
all stated they discuss the patients’ expectations very extensively. Most plastic surgeons 
reported they only provide general information about possible complications to the patient. 
Furthermore, surgeons paid limited attention to the psychosocial impact of the failure (“I am 
not going to talk about sexuality explicitly, I think that’s not necessary. It is clear that she has 
a problem with her own body. I will not discuss that into depth.” – PCH 2).
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not report explicitly on this in the results. Moreover, there is a preponderance of I-BR 
patients included in this study, despite our efforts to include more A-BR patients. 
This imbalance may have influenced our findings. Further research is needed to evaluate 
similarities and differences between the two treatment modalities.
Conclusions
The impact I-BR failure has on the patient should not be underestimated or considered 
negligible compared to A-BR failure, and patients require the same high degree of 
attention and aftercare, specifically when taking the considerably higher rate of I-BR 
failures into account. For all patients with a failed-BR, explicit acknowledgement of 
their suffering and emotional well-being by their plastic surgeon is an important part 
of their recovery. Empathy and good clinical conversation skills of the surgeon may be 
more beneficial than immediately offering additional psychosocial interventions. However, 
plastic surgeons may have difficulty with this, as they are still struggling with their own 
emotional response to the BR-failure. Interventions could focus on a safe and supportive 
debriefing environment for the surgeons to discuss the BR-failure with colleagues. Such 
interventions could ultimately improve the well-being for both the patient and surgeon.
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is exactly the period when the patient’s need for a conversation about the failure is the 
highest. We found that surgeons’ feelings of failure, self-doubt and guilt were present 
during this phase. Dealing with the emotions of the patients and their family has been 
reported to be particularly difficult when physicians are dealing with unresolved emotional 
reactions themselves.6,7,12 In our study, one plastic surgeon reported that seeing the patient 
with a failed BR was a constant reminder of the time he/she had failed. Addressing the 
emotional impact of the BR-failure for the patient would make the suffering of patients very 
tangible, and, in that way, confronting.
Another returning theme in the interviews was the desire of the patients to understand 
what the choice for a particular type of BR would mean for them as a person. They stated 
that almost all the information they had received, had been focused (too) exclusively on 
medical-technical information and the aesthetic results. This is in line with the findings 
of previous studies regarding information provision about BR.3,13,14 Patients in our study 
specifically stated they would have liked to be informed on the psychosocial impact of 
a BR and/or BR-failure. Paying attention to these aspects may also benefit the entire 
consultation, as patients experience the conversation as more personal. Acknowledging 
beforehand that the BR procedures may have a substantial psychosocial impact may also 
help patients deal with these issues more effectively in case they occur.15 
A final important result of our study is the discrepancy between the views of patients and 
plastic surgeons regarding the necessity to perform repeat surgery after the BR-failure. 
Some surgeons seemed to assume that almost all patients want a redo of their BR. 
However, this was not what we found in the patient group. A large proportion of patients 
reported they did not necessarily want a redo of the BR and listed numerous reasons 
for this. After the BR-failure, patients have gained firsthand experience on what it means 
to undergo a BR followed by a severe complication, something which almost all stated 
they did not have a clear idea about beforehand. A previous study showed that 
complication risk is a major factor in influencing patient decision making regarding 
future BR procedures.16 Surgeons may experience feelings of guilt that they have not 
been able to give the patient what they came for and experience a strong urge to fix 
this. It is therefore important to thoroughly review the patient’s motives before making a 
well-informed, shared and considered decision on whether or not to undergo a repeat BR.
Strengths and limitations of the study
The current study is a retrospective, qualitative analysis of the experiences of both 
patients and plastic surgeons with the occurrence of BR-failure. The retrospective nature 
of this study holds the risk of recall-bias. Memories of the events related to the BR-failure 
may have been colored by the outcome, current feelings about BR and the BR course. 
A strength of this study is that all interviews were independently analyzed by both a 
psychologist (L.H.) and a medical doctor (C.K.) to minimize bias that could originate 
from either respective professional perspective. The current study was not designed to 
compare differences in the impact of BR-failure between A-BR and I-BR and as such does 
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De studie gepresenteerd in hoofdstuk 2 laat zien dat een dergelijke, ogenschijnlijk 
eenvoudige uitkomstmaat, op betrouwbare en valide wijze kwaliteit van leven na 
borstkankerchirurgie evenals borstreconstructie (BR) kan meten.4
In een groot multicenter cross-sectioneel vragenlijstonderzoek (hoofdstuk 3) werd de 
kwaliteit van leven gemeten met de EQ-5D-5L bij patiënten na borstkanker. In de studie 
waren patiënten betrokken na BCT, alleen mastectomie, en mastectomie gevolgd door 
implantaat BR of autologe BR. De studie toonde de toegevoegde waarde aan van het 
sparen of reconstrueren van de borst boven alleen het uitvoeren van een mastectomie.5 
Er werden daarentegen geen statistisch significante verschillen in overkoepelende 
gezondheidsgerelateerde kwaliteit van leven uitkomsten gevonden tussen patiënten na 
BCT, implantaat BR en autologe BR. Postoperatieve complicaties hadden echter een 
grote en langdurige negatieve invloed op de kwaliteit van leven van patiënten, met name 
na autologe BR.
 
Kosteneffectiviteit van chirurgische behandeltrajecten 
van borstkanker
De zorgbudgetten staan zwaar onder druk door stijgende zorgkosten. De maatschappij, 
beleidsmakers en verzekeringsmaatschappijen staan daarom voor complexe keuzes over 
vragen als welke medische behandelingen in het basispakket van de zorgverzekeringen 
opgenomen moeten worden, welke behandelingen moeten blijven, en welke behandelingen 
plaats moeten maken. De kosteneffectiviteit van behandelingen is hierbij een belangrijk 
argument. Dit is niet alleen van belang bij de keuze tussen verschillende chirurgische 
behandelingen voor borstkanker, maar ook ten aanzien van de vraag wanneer de 
vergoeding van deze chirurgische behandelingen concurrerend is met andere toewijzingen 
van het zorgbudget. Dit is met name relevant voor veel voorkomende chirurgische 
behandeltrajecten voor borstkanker, zoals BR, omdat deze niet levensverlengend zijn, 
en waarbij de ‘medische noodzaak’ dus meer ter discussie staat.
Om deze reden is er een formele ‘state-of-the-art’ kosten-batenanalyse uitgevoerd 
(hoofdstuk 4). Deze niet-gerandomiseerde, multicenter-cohort kosteneffectiviteitsanalyse 
geeft aan dat BCT het meest kosteneffectieve alternatief is, wanneer de borst gespaard 
of gereconstrueerd wordt.6 Zowel implantaat BR als autologe BR waren aanzienlijk duurder 
dan BCT, met nauwelijks extra voordelen (QALY’s). Dit maakt dat zij niet te bestempelen 
zijn als kosteneffectieve alternatieven boven BCT.
Als een borstreconstructie na mastectomie wordt overwogen, lijkt implantaat BR de meest 
kosteneffectieve techniek te zijn. Eén van de redenen voor de gunstigere kosteneffectiviteit 
van implantaat BR ten opzichte van autologe BR is dat de relatief vaak optredende 
complicaties van autologe BR een onevenredig grote invloed hebben op kwaliteit van 
leven en kosten. Dat blijft zelfs zo als er rekening gehouden wordt met heroperaties als 
gevolg van complicaties bij implantaten op de lange termijn, zoals implantaatruptuur of 
kapselcontractuur.
Waarom zouden we borstkanker patiënten 
meer borstsparende therapie moeten  
adviseren
In de gezondheidszorg zijn interventies er doorgaans op gericht het leven van de patiënt 
te verlengen en/of de kwaliteit van leven te verbeteren. Deze twee aspecten, een langere 
levensduur en een betere kwaliteit van leven, worden gecombineerd in de uitkomstmaat 
Quality Adjusted Life Years (QALY’s). 
 
Patiënten bij wie borstkanker is vastgesteld, zullen zich over het algemeen concentreren 
op het eerste doel: zij willen de kanker overleven. Na de diagnose bestaat de eerste 
keuze, die een patiënt met borstkanker en haar chirurg samen zullen moeten maken, 
uit een borstsparende operatie gevolgd door radiotherapie (borstsparende therapie, ofwel 
breast conserving therapy: BCT) of een borstamputatie (mastectomie). Indien zij kiezen 
voor een mastectomie, zal de patiënt voor een vervolgkeuze komen te staan: of en hoe 
zij haar borst wil laten reconstrueren. 
In dit proefschrift werd onderzocht wat deze keuzes betekenen voor de patiënt, maar ook 
voor de samenleving, die de kosten draagt van de behandelkeuzen.
Kwaliteit van leven na borstkankerchirurgie
Eerdere studies hebben zich begrijpelijkerwijs hoofdzakelijk gericht op de gevolgen van 
de keuze voor één van deze chirurgische behandelingen op de levensverwachting van 
de patiënt. Uit meerdere betrouwbare studies is gebleken dat BCT geassocieerd is met 
een gelijke of zelfs iets gunstigere overleving bij patiënten met een vroeg stadium van 
borstkanker vergeleken met een mastectomie.1-3 Omdat de overlevingsresultaten na 
mastectomie en BCT nagenoeg gelijk en tegelijkertijd relatief goed zijn,1 wordt kwaliteit 
van leven na borstkankerbehandeling steeds belangrijker.
Er zijn veel meetinstrumenten ontwikkeld om op betrouwbare wijze de kwaliteit van 
leven van borstkankerpatiënten te kwantificeren, elk met zijn voor- en nadelen. Talrijke 
overheidsadviesorganen zoals NICE en ZiNL hebben echter gepropageerd dat als kwaliteit 
van leven wordt gebruikt om de waarde van verschillende behandelingen te vergelijken, 
de gebruikte meetinstrumenten in staat moeten zijn QALY’s te berekenen. Verschillende 
instanties raden hiervoor het gebruik van de EQ-5D aan. De EQ-5D is een generieke 
gezondheidsgerelateerde kwaliteit van leven vragenlijst gebaseerd op de voorkeuren 
van de algemene Nederlandse bevolking voor specifieke gezondheidsuitkomsten. 
Het meetinstrument bestaat uit 5 items, die problemen met mobiliteit, zelfzorg, dagelijkse 
activiteiten, pijn/ongemak en angst/depressie meten.
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De uitkomsten gepresenteerd in hoofdstuk 3 toonden aan dat specifiek na autologe BR 
dergelijke complicaties geassocieerd zijn met een grote en langdurige negatieve invloed 
op de kwaliteit van leven.5 Daarnaast liet het kwalitatieve onderzoek (hoofdstuk 5) zien 
dat als een complicatie leidt tot een totaal falen van de BR, dit gepaard gaat met een grote 
negatieve impact op zowel de patiënt als de chirurg.11
Belangrijke aspecten die naar voren kwamen (hoofdstuk 5) en waarmee rekening moet 
worden gehouden bij counseling van patiënten, zijn dat patiënten behandeld zouden willen 
worden met meer aandacht voor hun persoonlijke situatie, waarbij zij ook inzicht willen 
verkrijgen in de vraag welke invloed de chirurgische behandelingen op hun persoonlijke 
leven kunnen hebben, in plaats van een voorlichting vanuit een puur medisch-technisch 
perspectief.
Na een gefaalde BR kunnen de chirurgen schuldgevoelens ervaren die ook kunnen leiden 
tot een sterke drang om de mislukte BR te herstellen, terwijl patiënten juist minder geneigd 
zijn om aanvullende operaties te ondergaan. Daarnaast bleek dat de impact van het falen 
van een implantaat BR op een patiënt makkelijk kan worden onderschat door de chirurg. 
Voor patiënten met een gefaalde implantaat BR is dezelfde mate van intensieve nazorg en 
aandacht vereist als voor patiënten met een mislukte autologe BR.
De counseling van borstkankerpatiënten die een borstreconstructie wensen wordt verder 
nog gecompliceerd door een toenemend aantal studies die een groter risico laten 
zien dan eerder werd aangenomen op het ontwikkelen van de zeldzame en potentieel 
dodelijke aandoening anaplastisch grootcellig lymfoom (BIA- ALCL) voor vrouwen met 
een borstimplantaat.12 Dit nieuws is op grote schaal door de media opgepikt en heeft in 
sommige landen geleid tot een verbod op bepaalde typen borstimplantaten. Dat heeft 
op zijn beurt geleid tot angst en veel vragen bij patiënten die eerder een implantaat BR 
hebben ondergaan en bij patiënten die op het punt staan een keuze te maken of en welk 
type BR zij zouden kiezen. Speciale inzet zou moeten worden geleverd door plastisch 
chirurgische beroepsverenigingen om een evidence-based hulpmiddel te ontwikkelen 
voor het begeleiden van chirurgen en patiënten bij het maken van goed gefundeerde 
keuzes over BR.
Tenslotte is het belangrijk zich te realiseren dat borstsparende operatie altijd wordt gevolgd 
door radiotherapie met de daarbij onvermijdelijke kans op lange-termijn-bijwerkingen. 
Het aantal overlevenden van borstkanker neemt toe evenals de levensverwachting, 
waardoor onderzoek naar de schadelijke lange-termijn-effecten van radiotherapie steeds 
belangrijker wordt om strategieën te ontwikkelen voor het verminderen van de risico’s en 
het verbeteren van onze voorlichting en begeleiding van borstkankerpatiënten.
 
 
Er bestaan nog steeds grote verschillen tussen landen in de mate waarin BCT en 
mastectomie worden uitgevoerd. In Denemarken is bijvoorbeeld het gemiddelde aandeel 
BCT ongeveer 68% van alle chirurgische borstkankerbehandelingen. In Nederland is dat 
ongeveer 59%.7 Dit suggereert dat er ruimte is voor veranderingen in de keuzes voor 
behandeling en voor counseling daarin.
De hogere kosten verbonden aan BR zijn niet alleen relevant vanuit een financieel 
perspectief. Zij zijn een rechtstreeks gevolg van langer durende operaties, meer zieken-
huisopnames en de noodzaak tot inzet van meer personeel; aspecten die alle op zichzelf 
van belang zijn wanneer de schaarse middelen in de gezondheidszorg op een verantwoorde 
wijze moeten worden verdeeld.
Een ontwikkeling op het gebied van BCT is de opkomst en ontwikkeling van oncoplastische 
chirurgie. Bij oncoplastische chirurgie bundelen oncologisch chirurgen en plastisch 
chirurgen hun krachten om de inzetbaarheid van borstsparende chirurgie uit te breiden, 
zodat grotere tumoren en tumoren met een ongunstige locatie verantwoord behandeld 
kunnen worden, wat anders zou hebben geleid tot ongunstige/ onaanvaardbare 
cosmetische resultaten.8, 9 Er zullen verdere studies moeten worden uitgevoerd om te 
onderzoeken of de samenwerking inderdaad leidt tot een betere kwaliteit van leven en 




Counseling van borstkankerpatiënten die een mastectomie moeten ondergaan is 
belangrijk. Het is in dit kader belangrijk om te beseffen dat BR geen levensreddende 
behandeling is, het wordt daarom ook wel ‘electieve chirurgie’ genoemd. Omdat BR als 
doel heeft de vorm van de borst te herstellen, zou het zelfs een cosmetische ingreep 
genoemd kunnen worden. 
Omdat bij BR risico’s zijn verbonden aan de operatie en de waardering van een 
gereconstrueerde borst afhankelijk is van de patiënt, is de kwaliteit van het gesprek tussen 
chirurg en patiënt nog belangrijker, dan wanneer alleen risico’s moeten worden afgewogen 
tegenover zoiets evidents als een substantiële kans op overleven. In dat laatste geval 
is het voor de chirurg gemakkelijker om in de schoenen te staan van de patiënt. In het 
geval van een weging tussen de vorm van de borst en het risico op en de ernst van 
complicaties, is het echt een zaak van weging door de patiënt.
Zowel implantaat BR als autologe BR zijn geassocieerd met een relatief hoog risico 
op complicaties. Een recent groot prospectief onderzoek door Bennet et al. vond 
complicatiepercentages van ongeveer 26% voor implantaat BR (waarbij 15% een 
heroperatie nodig had) en ongeveer 47% voor autologe BR- technieken (waarbij 29% een 








Bovenstaande leidt tot een superieure (kosten-)effectiviteit in vergelijking met behandeling 
d.m.v. een borstamputatie al dan niet gevolgd door BR. Daarom is BCT een goed start-
punt voor een consult over de mogelijke behandelopties aan patiënten met borstkanker 
(hoofdstuk 6).13 In dit consult wordt voorlichting gegeven over: de verschillen tussen BCT 
en andere chirurgische behandelingen met betrekking tot de overleving, de verwachte 
kwaliteit van leven, cosmetische resultaten, bezoeken aan het ziekenhuis, mogelijke 
complicaties en de schadelijke effecten van aanvullende oncologische behandelingen 
zoals bestraling. Verder dient in dit consult ruimte te zijn voor bespreken van de waarde 
die de individuele patiënt hecht aan deze aspecten van haar behandeling, het proces en 
de uitkomst. Op basis hiervan kan in samenspraak de behandelkeuze worden gemaakt.
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